AU669502B2 - Quinolone- and naphthyridone-carboxylic acid derivatives - Google Patents

Quinolone- and naphthyridone-carboxylic acid derivatives Download PDF

Info

Publication number
AU669502B2
AU669502B2 AU31054/93A AU3105493A AU669502B2 AU 669502 B2 AU669502 B2 AU 669502B2 AU 31054/93 A AU31054/93 A AU 31054/93A AU 3105493 A AU3105493 A AU 3105493A AU 669502 B2 AU669502 B2 AU 669502B2
Authority
AU
Australia
Prior art keywords
cyclopropyl
oxo
diazabicyclo
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU31054/93A
Other versions
AU3105493A (en
Inventor
Klaus-Dieter Dr. Bremm
Rainer dr. Endermann
Klaus Dr. Grohe
Ingo Dr. Haller
Andreas Dr. Krebs
Karl-Georg Dr. Metzger
Uwe Dr. Peterson
Thomas Dr. Philipps
Thomas Dr. Schenke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27203290&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU669502(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4200414A external-priority patent/DE4200414A1/en
Priority claimed from DE4208789A external-priority patent/DE4208789A1/en
Priority claimed from DE4208792A external-priority patent/DE4208792A1/en
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU3105493A publication Critical patent/AU3105493A/en
Application granted granted Critical
Publication of AU669502B2 publication Critical patent/AU669502B2/en
Assigned to BAYER HEALTHCARE AG reassignment BAYER HEALTHCARE AG Alteration of Name(s) in Register under S187 Assignors: BAYER AKTIENGESELLSCHAFT
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Request to Amend Deed and Register Assignors: BAYER HEALTHCARE AG
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Fodder In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Description

L
Our Ref: 453000 P/00/011 Regulation 3:2
AUSTRALIA
Patents Act 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT q
S
';4 444 Applicant(s): Address for Service: Bayer Aktiengesellschaft D-5090 Leverkusen Bayerwerk
GERMANY
DAVIES COLLISON CAVE Patent Trade Mark Attorneys Level 10, 10 Barrack Street SYDNEY NSW 2000 Quinolone- and naphthyridone-carboxylic acid derivatives Invention Title: The following statement is a full description of this invention, including the best method of performing it known to me:- 5020 l I- The invention relates to new quinolone- and naphthyridonecarboxylic acid derivatives, processes for their preparation and also antibacterial agents and feed additives containing them.
Quinolone- and naphthyridonecarboxylic acids which are substituted in the 7-position by a bicyclic amine radical have already been disclosed in EP-A-0,350,733.
The present invention relates to new compounds of the formula (I) rrr r ii trs ~t r r
)OR
2 in which oori; o 41 6 I 0 *f A represents CH, CF, CC1, C-OCH 3
C-CH
3 or N,
X
1 represents H, halogen, NH 2 or CH 3
R
1 represents C 1
-C
3 -alkyl, FCH 2 CHz-, cyclopropyl or phenyl which is optionally monosubstituted to trisubstituted by halogen, or A and R 1 together can denote a bridge of the structure C-O-CH 2
-CH(CH
3 Le A 28 100 1 k j I *2 represents H, Cl-C 3 -alkyl which is optionally substituted by hydroxyl, halogen or amino or methyl.-2-oxo-1, 3-dioxol-4-yl-methyl, B represents a radical of the formulae 1 R 3 N PY
N
H H
R
4
Y
N
H H H R4N Y R 4
N'~
in which 00 0 00 0 0*0004 r ~0
A
404.
Y represents 0 or CH 2 1 3 represents C,-C 5 -oxoalkyl, CH 2
-CO-C
6
H
5
CH
2
CH
2
CO
2
RI,
R'0 2
C-CH=C-CO
2
-CH=CH-CO
2 R' or CH 2
CH
2
-CN,
in which R' denotes hydrogen or Cl-C 3 -alkyl, 4 represents H, Cl-C 3 -alkyl, C 2 -C-oxoalkyl, CH 2
-CO-
CAH, CH 2
CH
2
CO
2 RI, R'O 2 C-CH= 5 -C0 2
-CH=CH-CO
2 R' or
CHCH
2 -CN or represents 5-methyl-2-oxo-l, 3-dioxol-4 yl-methyl, in which R' denotes hydrogen or C-C 3 -alkyl, Le A 28 100 -2
L
-I and to pharmaceutically utilisable hydrates and acid addition salts thereof as well as the alkali metal, alkaline earth metal, silver and guanidinium salts of the underlying carboxylic acids. These compounds have a high antibacterial activity. The compounds according to the invention are particularly distinguished in that they have a high activity on dormant and resistant microorganisms.
Preferred compounds of the formula are those in which A represents CH, J7, CC1, C-OCH 3 or N,
X
1 represents H, F, Cl, Br, NH, or CH 3
R
1 represents C 2 H, cyclopropyl or 2,4-difluorophenyl, or A and R 1 together can denote a bridge of the structure C-O-CH 2
-CH(CH
3
R
2 represents H, CH 3 CzHg or 5-methyl-2-oxo-l,3-dioxol- 4-yl-methyl, otrr ror ri~rr r ~rir o 1 t, rrrr 1
B
N
RN Y represents a radical of the formulae
N
H- H 4H H RN Y h
N
H H RH N Y
N
RN Y
N
RN Y in whic Le A 28 100 3 ii I I i- Y represents 0 or CH 2 and R 3 represents CH 2
-CD-CH
3
CH
2
-CO-C
6
H
5
CH
2
CH
2
-CO-CH
3
CH
2
CH
2
CO
2 RI, R' 0 2
C-CH=C-CO
2
-CH=CH-CO
2 R' or
CH
2
CH
2
-CN,
in which R' denotes C-C 2 -alkyl.
R 4 represents H, Cl-C 3 -alkyl, 5-methyl-2-oxo-1, 3-dioxol- 4-yl -methyl, CH 2
-CO-CH
3 1 CH 2
-CO-C
8
H
5 I CH 2
CH
2
-CO-CH
3
CH
2
CH
2
CO
2 R'0 2
C-CH=C-CO
2
-CH=C:H-CO
2 R' or CH 2
CH
2
-CN,
in which R' denotes Cl-C 2 -alkyl.
Particularly preferred -ompounds of the formula are those in which A represents CH, CF, CCl, C-OCH 3 or N, X1 represents H, F, Cl, Br, NH 2 or CH 3
R
1 represents C 2
H
5 I cyclopropyl or 2,4-difluorophenyl, or A and R1 together can denote a bridge of the structure C-O-CH 2 -CH (CH 3 #004 Le A 28 100-4 4 7- 2_ R represents H, CH 3 or CAH,
B
2 represents a radical of the formulaeHH RN Y RN Y R 4N Y R N Y in which Y represents 0 or CH 2 and R 4 represents H, Cl-C 3 -alkyl, 5-methyl-2-oxo-l, 3-dioxola 44 4-yl-methyl, CH 2
-CO-CH
3
CH
2
-CO-C
6
H
5
CH
2
CH
2
-CO-CH
3
CH
2
CH
2
CO
2 R1, R'0 2
C-CH=C-CO
2
-CH=CH-CO
2 R' o:r 1 CH CH -CN, in which R' denotes Cl-C-alkyl.
The compounds of the formula (I) in which b44.1 1 4 A, X ,R and R 2 have the abovementioned meaning, and B represents a radical of the formula Le A28 100
N
RN Y in which R R 3 and Y have the abovementioned meaning, I are obtained by reacting a compound of the formula (II) F 00R 2 INA N 11(II) HN
R,
U Y in which 1 1 A, Y, X ,R1 and R 2 have the abovementioned meaning, with a compound of the formula (III) in which Le A28 100 -6 16- .17 ~I _I~
R
3 represents C 2
-C
5 -oxoalkyl, CH 2
-CO-C
6 Hs, CH 2
CH
2
-CO
2 R' or
CH
2
CH
2
-CN,
in which R' denotes hydrogen or C 1
-C
3 -alkyl, and
X
3 represents halogen, in particular chlorine, bromine or iodine, if appropriate in the presence of acid binders. [Method A] Compounds according to the invention of the formula (I) in which a 9 A, X R 1 and R 2 have the abovementioned meaning, and B represents a radical of the formula
N
RN Y Sin which Y has the abovementioned meaning and i Le A 28 100 7- L hsteaoeetoe m. an R'0 2 C-CH=C-COAR', -CH=CH-CO 2 R' or CH 2
CH
2
-CN,
in which R' denotes hydrogen or C 1
-C
3 -alkyl, can be obtained by reacting a compound of the formula (II) 0 F COOR 2 N A N HN RI
SY
(II)
with a Michael acceptor such as dialkyl acetylenedicarboxylate, alkyl propiolate or a compound of the formula (IV)
CH
2
=CH-R
5
(IV)
in which
R
5 represents COCH 3
CO
2 R' or CN. [Method B] To prepare enantiomerically pure compounds of the formula a compound of the formula (V)
I
,jri a c rr r Le A 28 100 8 i I
X
I
F COOR2 X N i I ]I I i i i i i i, i i i j j t D0* in which A, R 1
R
2 and X 1 have the abovementioned meaning and
X
2 represents halogen, in particular fluorine or chlorine, is reacted with enantiomerically pure compounds of the formulae (VI) H H N N H H H H H (VI) RN Y RN Y in
Y
R
4 which represents O or CH 2 and represents H or C-C 3 -alkyl, Le A 28 100 9 I r L .i if appropriate in the presence of acid scavengers, and the reaction product is optionally further reacted with a compound of the formula (Ila) R 4
_X
3 (IIla) in which X 3 has the abovementioned meaning and iI 4 R represents C 2
-C
5 -oxoalkyl, CH 2
-CO-C
5
H
5
CH
2
CH
2
CQ
2 R' or
CII
2
CH
2
-N
in which R' denotes hydrogen or Cj-C-alkyl, or with a Michael acceptor such as dialkyl acetylenedicarboxylate, alkyl propiolate or a compound of the formula (IV)
CH
2 =CH-R' (IV) Q 15 in which
R
5 represents COCH 3 1 CO 2 R' or CN [Method C].
If, for example, 8-chloro-1-cyclopropyl-6,7-difluoro-1,4- I dihydro-4-oxo-3-quinolinecarboxylic acid and Le A28l100-10ii diazabicyclo[4.3.O]nonane are used as starting compounds, the course of the reaction can be represented by the following reaction scheme:
COOH
I
C1 t1 o q 4 9941
COOH
CII
If, for example, 6,8-difluoro-l-(2,4-difluorophenyl)-l,4dihydro-7-([lS,6R)-2-oxa-5,8-diazabicyclo[4.3.O]non-8yl )-4-oxo-3-quinolinecarboxylic acid and diethyl acetylenedicarboxylate are used as starting substances, the course of the reaction can be represented by the following reaction scheme:
COOH
2 5
O
2 C-C=C-CO2 2 C2HH
HN>YI
Le A 28 100 11 0 F COOH
CO
2
C
2
H
I N
C,H
5 2 C-CH=C F F
F
The racemic compounds of the formula (II) used as starting compounds are mainly known. Enantiomerically pure compounds of the formula (II) are new and can be S, obtained in various ways.
1. A racemic intermediate of the formula (II) is reacted with an enantiomerically pure auxiliary reagent, the resulting diastereomers are separated, for example by chromatography and the chiral auxiliary group is removed again from the desired 10 diastereomer. The following reaction may be shown as an example: F 2 COOH (R) N C+ H-NCO SHN c i F CH 3 Le 2 cis 101 Le A 28 100 12- I .i COOH Diastereal~r
(R)
CH- NH-COI I N
CH
3 se-paration
HE)
F COOR
N
H H~NH-COH
NF
a I
~N
CH
3 04 4 004 0 0444 #000 004 I 00 4
COOR
4 4 2. The bicyclic amines (VI) are, as enantiomerically pure compounds, new. They can be prepared by the following processes: 2.1. The racemic bicyclic amines (a)
CN,
rn
NH
in which R 4 represents H or C 1 -C.-alkyl, Le A28 100 13 i AI can be reacted with enantiomerically pure acids, for example carboxylic acids or sulphonic acids such as N-acetyl-L-glutamic acid, N-benzoyl-L-alanine, 3bromocamphor-9-sulphonic acid, camphor-3-carboxylic acid, cis-camphoric acid, camphor-10-sulphonic acid, O,0'-dibenzoyl-tartaric acid, D- or L-tartaric acid, mandelic acid, a-methoxy-phenylacetic acid, 1phenyl-ethanesulphonic acid or a-phenyl-succinic acid, to give a mixture of the diastereomeric salts, which can be separated by fractional crystallisation to give the diastereomerically pure salts (see P.
Newman, Optical Resolution Procedures for Chemical Compounds, Volume The molar ratio between amine and enantiomerically pure acid can be varied in a 15 relatively wide range. By treatment of these salts with alkali metal or alkaline earth metal hydroxides, the enantiomerically pure amines can be liberated.
2.2. In a similar manner, as described in 2.1., resolution of the basic intermediates which occur during the preparation of the racemic bicyclic i9 amines can be carried out using the abovementioned enantiomerically pure acids. Examples of basic Sintermediates of this type are: I*t i Le A 28 100 14 ,1 I -i -r CH2 (b)
N
N CH 2
(C)
CH
2 N.
CN CN O- (d) 0
CH
2
__O
N
.C
NH
I'
I,.
4i V 4 4 '33.
.ini In the following reaction scheme, the separation of 8-benzyl-cis-2,8-diazabicyclo[4.3.O]nonane into the enantiomers via the tartrates and conversion thereof into the enantiomerically pure cis-2,8diazabicyclo[4.3.O]nonanes may be shown as an example of a resolution: Le A28 100 C _CN-C
H
2 -Ph -tartaric acid e0~ 0 0 4 0*04 000401 0 3 0 1. Crystallisation t1) 1 x recrystallis 2) NaOH
N-CH
2 -Ph
H
I H2 Pd-C 1 1 14, 2. Crvstallisation Mother liqu 1) NaOH ation L 1 x recryst. 2) tartaric VI NaOH acid R H or 00 01 0 0040 0044 0 4 I H 2 Pd-C
HH
I H
N-H
99 R, R-Configuration 99 S,S-Configuration Le A 28 100 16 2.3. Both the racemic amines and the basic intermediates can be separated by chromatography, if appropriate after acylation, by means of chiral support materials (see, for example, G. Blaschke, Angew. Chem. 92, 1411980]).
2.4. Both the racemic amines and the basic intermediates can be converted by chemical linkage with chiral acyl radicals into diastereomer mixtures which can be separated by distillation, crystallisation or chromatography into the diastereomerically pure acyl derivatives, from Vj which the enantiomerically pure amines can be 'i isolated by hydrolysis. Examples of reagents for Ij linkage to chiral acyl radicals are: a-methoxy-a- S 15 trifluoromethyl-phenylacetyl chloride, menthyl isocyanate, D- or L-a-phenyl-ethyl isocyanate, menthyl chloroformate or chloride.
In the course of the synthesis of the bicyclic 20 amines instead of achiral protective groups chiral protective groups can also be introduced. In this manner, diastereomers are obtained which can be separated. For example, in the synthesis of cis-2,8diazabicyclo[4.3.0]nonane, the benzyl radical can be replaced by the R- or S-a-phenylethyl radical: iL Le A 28 100 17-
I
-i
N
N-CH O CH3
-CH
CH
3 ~rna oooo a ~e 00 a ~oo 0000 olaa~ arrr~~~ 0 00 06 00 a 00 09 a a a a 00 0 2.6. The enantiomerically pure amines (VI) can also be synthesised from enantiomerically pure precursors, such as, for example, or [S,S]-3,4-dihydroxypyrrolidine, which should be protected on the nitrogen by a protective group.
An example of the synthesis of an enantiomerically pure amine, starting from enantiomerically pure 1-benzyl-3,4dihydroxy-pyrrolidine, which may be given is the following reaction scheme: HO OH HO OH HO OCH 2
CH
2
OH
a,b c,d e N N N ~r il~ r o i r.i
Q'
rr o 0000 0 t 0000 TosO OCH 2
CH
2 OTos
N
O N-Bzl
N
g,h Zbh O N-H
H.
H
Le A 28 100 18 ,r I _I ii
L
tttf'4 *4 4~ OtUt a: d: for example, (CH 3 3 C-0,
H
2 1 Pd/A-carbon acylation NaH, BrCH 2
COOC
2
H
5 or c: CH 2
=CH-CH
2 Br, NaH, LiBH 4 d: 03, NaBH 4 tosyl chloride, NEt 3 benzylamine, xylene, ref lux hydrolys is
H
2 Pd/A-carbon Examples of compounds of the formula (VI) which may be mentioned are: cis-2 -diazabicyclo[4 0]nonane, 8-diazabicyclo 3 nonane, trans-2-oxa-5,8-diazabicyclo[4 .3 .0]nonane, 15 S,S-2,8-diazabicyclo[4.3.0]nonane, IR, 6S-2-oxa-5, 8-diazabicyclo [4 nonane, IS,6R-2-oxa-5,8-diazabicyclo[4.3.0]nonane, IR,6R-2-oxa-5,8-diazabicyclo[4.3.0]nonane, IS, 6S-2 -oxa-5 ,8-diazabicyclo [4.3.0 ]nonane, The reaction of with (VI) in which the compounds (VI) can also be employed in the form of their salts, such as, for example, the hydrochlorides, is preferably carried out in a diluent such as dimethyl sulphoxide, N,N-dimethylformanide, N-methylpyrrolidone, hexamethyl- 25 phosphoramide, sulpholane, acetonitrile, water, ai f alcohol such as methanol, ethanol, n-propanol or isopropanol, glycol. monomethyl ether or pyridine.
Mixtures of these diluents can also be used.
Le A28 100 19- 4' Lr- Acid binders which can be used are all the customary inorganic and organic acid binding agents. These preferably include the alkali metal hydroxides,, alkali metal carbonates, organic amines and amidines. Those which may be mentioned specifically as being particularly suitable are: triethylamine, 1,4-diazabicyclo- [2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or excess amine (VI).
The reaction temperatures can be varied within a relatively wide range. In general the reaction is carried out between about 20 and 200°C, preferably between 80 and S180°C.
t The reaction can be carried out at normal pressure, but also at elevated pressure. In general, it is carried out 15 at pressures between about 1 and 100 bar, preferably between 1 and 10 bar.
j When carrying out this process, 1 to 15 mol, preferably o 1 to 6 mol of the compound (VI) are employed per mol of the compound 20 Examples of compounds of the formula (II) which can be Sused both as racemates and as enantiomerically pure or diastereomerically pure compounds which may be mentioned are: Le A 28 100 L .J ic X1
C-R
F
N A N (i
N
RR2X' Y A Cylpoy 25H CH-i C-H
F-CH
2
CH-
2 H H CH 2
C-F
Cyclopropyl C 2 5 H C 2 C-Cl Cyclopropyl H H Cl- 2
C-OCR
3 Cyclopropyl H H CR 2
C-CR
3 Cyclopropyl C 2
H
5 H CH 2
N
Cyclopropyl H Br CH 2
C-F
Cyclopropyl H Cl CR 2
C-F
Cyclopropyl H Cl- 3 CH, C-F Cyclopropyl CH 5
NH
2
CH
2
C-F
Cyclopropyl H H 0 C-H Cyclopropyl C 2
H
5 H- 0 C-F
C
2
H
5 H 141 0 C-Cl
CH
3 H H 0 C-OCH 3 o ylorpl3 CH 3 Cyclopropyl H H 0 N-H 9'Cyclopropyl H Br 0 N- Cyclopropyl H Br 0 C-F Cyclopropyl R CR 3 0 C-F Cyclopropyl H NH 2 0 C-F Le A 28 100 -21- 0000 00 00 0 040 0 0:0000 000000 0400 Cylopoy Cyclopropyl Cyclopropyl Cyclopropyl Cyclopropyl Cyclopropyl Cyclopropyl Cyclopropyl CyclIopro pyl Cyclopropyl Cyclopropyl Cyclopropyl
C
2
H
5 Cyclopropyl Cyclopropyl CyclIapropyl Cyclopropyl Cyclopropyl Cyclopropyl
CH
5
N
CH
3
CHCH
2
OH
CH
2
CH
2
OH
H-
H
H
H
H
H
H
H
CH
3
H
H
H
H
H
H
H
H
xl
H
H
H
H
H
H
Br
F
CH
3
NH
2
H
H-
H
H
H
H
Br
CI
CH
3
NH
2
Y
CH,
CH,
CH
2
CH
2
CH
2
CH,
CH
2
CH
2
CH
2
CH
2 0 0 0 0 0 0 0 0 0 0
-A
C-H
C-F
C-Cl C-0C-H 3
C-CH
3
N
C-F
C-F
C-F
C-F
C-H
C-F
C-Cl
C-OCH
3
C-CH
3
N
C-F
C-F
C-F
C-F
Le A28 100 22 xi 0 F
COOR
2 H N A N
(I
H N Cyclopropyl H H CH 2
C-H
Cyclopropyl H H OH 2
C-F
clopropyl H H CH 2
C-CL
Cyclopropyl H H CH 2
C-OCH
3 Cyclopropyl H H- CH 2
C-CH
3 Cyclopropyl H H CH 2
N
Cyclopropy] H Br f, H 2
C-F
Cyclopropyl H F CH 2
C-F
Cyclopropyl H CH OH 2
C-F
Cyclproyl H H C-H Cyclopropyl H H 0 C-F Cyclopropyl H H 0 C-Cl Cyclopropyl H H 0 C-OCH Cyclopropyl H H 0 C-OH 3 C1yclopropyl H H 0 N-CH Cylpop<HH4
-H
C yclopropyl H Br 0 C- Cyclopropyl H Fr 0 C-F Cyclopropyl H OH 0 C-F Cyclopropyl H NH 2 0 0-F Le A28 100 23- F xl COOR 2 HH N- A I (I N
A.
Cyclopropyl H H CH, C-H Cyclopropyl H H CH 2
C-F
Cyclopropyl H H CH 2 C-Cl Cyclopropyl H H CH 2
C-OCH
3 Cyclopropyl H H CR 2
C-CR
3 Cyclopropyl H H CR 2
N
000000poplH r C 2 00Cyclopropyl H Br CH 2
C-F
Cyclopropyl H FH CHI C-F Cyclopropyl H CR 3
CR
2
C-F
Cyloroy 00 0 C 0Cyclopropyl H H CR C-F 00Cyclopropyl H H 0 C-Hl Cyclopropyl H H 0 C-FCH 0000rpy H 0 C-H *Cyclopropyl H H 0 C-C Cyclopropyl H H 0 C-CH Cyclopropyl H H 0 N- 4Cyclopropyl H4 Br 0 C-F Cyclopropyl H FH 0 C-F Le A28 100 -24p.xi 0 F
COOR
2 N A N HN K
Y
R 2 X' Y A .4, 5451$ S C 2,4-Dif luorophenyl.H 2,4- Di f luorophenylH 2,4-Dif luozrophenylH 2,4-Di f luorophenylH 2,4-Dif luorophenylR 4-Fluorophenyl H 2,4. Dif luorophenyiR 2,4. Dif luorophenylH 2,4-Dif luorophenylH 2,4-Dif luorophenylH 2,4-Dif luorophenylH 24-Di fluorophenylHi 2,4- Dif luorophenylH 2,4- Dif luorotphe-nyiH 2,4-Dif luorophenYlH-
Z
24 -Dif luoroohenylHfluorophe nylC 2
H
5 Cl CR 2
C-F
CH
3
CH
2
C-F
H CH 2
C-CH
3 H 0 C-F H 0 C-Cl H 0 CH HO0N H 0 C-OCH 3 H 0 C-CH 3 H CH 2
C-F
F CH 2
C-F
H CH 2 C-Cl H 0 C-Cl H CH 2
N
HO0N H 0 C-H H 0 C-F Le A 28 100 25 The starting compounds of the structures (III) and (IV) are known. Examples which may be mentioned are: chloroacetone, 4-chloro-2-butanone, 5-chloro-2-pentanone, l-bromo-2-butanone, phenacyl chloride, methyl acrylates, ethyl acrylates, acrylonitrile, methyl vinyl ketone, dimethyl acetylenedicarboxylate, diethyl acetylenedicarboxylate, methyl propiolate and ethyl propiolate.
The reaction of (II) with (III) is preferably carried out in a diluent such as dimethyl sulphoxide, N,N-dimethylformamide, N-methylpyrrolidone, hexamethylphosphoramide, sulpholane, acetonitrile, water, an alcohol such as methanol, ethanol, n-propanol or isor "opanol, glycol Smonomethyl ether or pyridine in the presence of an acid binder. Mixtures of these compounds can also be used.
Acid binders which can be used are all the customary inorganic and organic acid binders. These preferably include the alkali metal hydroxides, alkali metal carbonates, organic amines and amidines. Those which may be specifically mentioned as being particularly suitable are: triethylamine, 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or excess amine (VI).
44 Eo*. The reaction temperatures can be varied within a relatively wide range. In general the reaction is carried out between about 20 and 200°C, preferably between 60 and 130 0
C.
Le A 28 100 26p.so e.
a.o a ar The reaction can be carried out at normal pressure, but also at elevated pressure. In general, it is carried out at pressures between about 1 and 100 bar, preferably between 1 and 10 bar.
When carrying out this process, 1 to 15 mol, preferably 1 to 6 mol, of the compound (III) are employed per mol of the compound (II).
The reaction of (II) with the Michael acceptors (IV) according to method B is preferably carried out in a diluent such as acetonitrile, dimethyl sulphoxide, N,Ndimethylformamide, an alcohol such as methanol, ethanol, propanol or isopropanol, or glycol monomethyl ether.
The reaction temperatures can be varied within a relatively wide range. In general, the reaction is carried out between about 20°C and about 150'C, preferably between 40"C and 100"C.
The reaction can be carried out at normal pressure, but also at elevated pressure. In general, the reaction is carried out at pressures between 1 and 100 bar, preferably between 1 and 10 bar.
When carrying out the process according to the invention, 1 to 5 mol, preferably 1 to 2 mol, of the compound (IV) are employed per mol of the compound (II).
L .f Le A 28 100 27 The preparation of the acid addition salts of the compounds according to the invention is carried out in a customary manner, for example by dissolving the betaine in aqueous acid and precipitating the salt with a watermiscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Equivalent amounts of betaine and acid can also be heated in water or .n alcohol such as glycol monomethyl ether and then evaporated to dryness or the precipitated salt filtered off with suction.
Pharmaceutically utilisable salts are understood as meaning, for example, the salts of hydrochloric acid, sulphuric acid, acetic acid, glycolic acid, lactic acid, succinic acid, citric acid, tartaric acid, Do methanesulphonic acid, 4-toluenesulphonic acid, 15 galacturonic acid, gluconic acid, embonic acid, glutamic oo acid or aspartic acid.
o 00 The alkali metal or alkaline earth metal salts of the carboxylic acids according to the invention are obtained, for example, by dissolving the betaine in excess alkali 20 metal or alkaline earth metal hydroxide solution, filtering off undissolved betaine and evaporating the filtrate to dryness. Pharmaceutically suitable salts are sodium, potassium or calcium salts. By reacting an alkali Smetal or alkaline earth metal salt with a suitable silver S 25 salt such as silver nitrate, the corresponding silver salts are obtained.
Apart from the active substances mentioned in the examples, for example, the compounds listed in the Le A 28 100 28 -L C following tables (optionally in the cis- or -trans-f o=) can also be prepared by the processes described:
COOH-
0000 0 1 0*0 00
CZH-
5 0 2 ZC-CHb-CH 2
CH
3
O:
2
C-CH--C--
NC-Cf- 2
-CHZ-
i5-Methyl-2-oxo- 3.,3-dioxot-4-yl-methyI- CHi 3
-CO-CH
2 5-Methyl-2-oxo. 1 3-dioxol-4-yl-methylj-
CI-
3
-CO-CH
2
-CH
2
CH
3
-CO-CH
2
C
2
H
5 0 2
C-CH
2
-CR
2
C
2
HSO
2 C-CH=C-CO C TH 3 CH-.i0 2
C-C-H=-CH-
C
2 fi 5
O
2 C-C1{=CH- CHY-C&-CH 2
CH,-
C
2 -30 2 C'CHf2CH 2
CH
3 0 2
C-CH=C-CO
2 1C' 3
C
2 14{-O2C-CH=C'0COC,H 5
C-F
C-F
C -F
C-F
C-cl
C-C!
C-H
c--
C-H-
C-H
C-i-i
C-F
C-F
C-F
C-F
C-F
INH,
INH,
NH,
INH,
-29 N0911700~ SHIAV'I 09OT999 9 TO-Z OV!~TT W6 VO/6Z F
COGH
4H -N A
N
R
N
C2H02-CXCl AH, C-F CH502C-CH2.CH2-
H
CH
5 0,C-CH-C-C0 2
C
2
H
5
H
CH
3 OiC-CH--CH-
HN
00CH 3
-CO-CH
2
CH
2 H H
CH
3
-CO-CH
2
CH
3
C-H
C
2 f! 5 0 2
C-CH
2
CH
2
CH
3
S
C
2
H
5
O
2
C-CH=C-COC
2
H
5
CH
3
C-H
:CH
3 0 2
C-CH-=C-CQ
2
CH
3
CH-
3
C-H
C
2
H
5 0 2 C-CH=CH-
CH-
3
C-H
CH
3
O
2 C-CH=CH-
CH
3
C-F
00CCHC-0C2i CH 3
N
LII
NOSI'1103 SHIAVI OSOT99 Z T9Q or:TT 96, Ito/6z ~0U V'61 2 2621080 29/04 '96 11: 40 DAVIES COLLISON [a 008 I2-D -H2D=HD-DZO'H2
-'HJDF-~OD£HD
-:H2YHDDOOH'D -HDH20r2-EH ~L H H JvO H dl 9* 9 99 49 a. 9~9.
0 4 440
A,
H000
.COOH
A L
I
0000 00 0 0 4 0000 00*004 0 0 4000 00
C'
2
H-
5 2 C-CH -C-CO 2
C-'H
5
C
2 th 5
O
2
C-C-=C.H-
C
2
,H
5 O2C-CH--CH-
C
2
H
5 O0 2
C-CH--CCO
2
C
2 f' 5
CH
3
-CO-CH
2
C-
CZH
5
OI.C-CH=CH-
C
2
H
5
O
2
C-CH=C-CO
2
C
2
H
5 C14 3 0 2 C-CH=C-C0 2
C
2
ZH
5
CH'
3
-CO-CH
2
CH
2
C.
2 HS(0 2 C-CH=CHi-
C
2
H
5 0 2
?C-CH=CH
NC-CH
2
CH
2
C"
3
-CO-CH
2
CH
2 xi A H C-H H C-H F C-F F C-F NH~ C-F NH, C-F
CH
3
C-H
CHS C-H
-F
3
C-NJ
cpl N H C-OCH 3 H C-OC- 3 H N H 'N 32 600 Z 6OO~~~~j ~NOSITIO0 SHIAVa ST9 9 TT 6 O6 09OT999 9 T9Q Of:TT 9C VO/69
IL
The compounds according to the invention have potent antibiotic activity and exhibit, together with low toxicity, a broad antibacterial spectrum against grampositive and gram-negative microorganisms, in particular against enterobacteria; especially even against those which are resistant to various antibiotics, such as, for example, penicillins, cephalosporins, aminoglycosides, sulphonamides and tetracyclines.
These useful properties make possible their use as chemotherapeutic active substances in medicine and also as substances for the preservation of inorganic and organic materials, in particular of organic materials of all types, for example polymers, lubricants, dyes, fibres, leather, paper and wood, of foodstuffs and of water.
o:00 The compounds according to the invention are active 0 against a very broad spectrum of mircoorganisms. With their aid, gram-negative and gram-positive bacteria and o:0o.: bacteria-like microorganisms can be controlled and the 0" 20 diseases produced by these pathogens can be prevented, ameliorated and/or cured.
'3 The compounds according to the invention are distinguished by increased activity on dormant and resistant microorganisms. In the case of dormant 25 bacteria, e.g. bacteria which show no detectable growth, o° the compounds act at concentrations which are far below those of substances known hitherto. This relates not only Le A 28 100 33- L .L r f I to the amount to be employed, but also to the rate of destruction. It was possible to observe results of this type with gram-positive and gram-negative bacteria, in particular with Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecalis and Escherichia coli.
The compounds according to the invention also show surprising increases in activity against bacteria which are classified as less sensitive to comparable substances, in particular resistant Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis.
The compounds according to the invention are particularly active against bacteria and bacteria-like microorganisms.
They are therefore particularly highly suitable for the prophylaxis and chemotherapy of local and systemic infections in human and veterinary medicine which are oo caused by these pathogens.
The compounds are also suitable for controlling protozoonoses and helminthoses.
The compounds according to the invention can be used in Svarious pharmaceutical preparations. Preferred pharmaceutical preparations which may be mentioned are tablets, coated tablets, capsules, pills, granules, *0""0S suppositories, solutions, suspensions and emulsions, S° 25 pastes, ointments, gels, creams, lotions, powders and f sprays.
Le A 28 100 34r L- The table below confirms the surprising advantages of the compounds according to the invention compared with ciprofloxacin in the Staphylococcus aureus-infected mouse model: Table: Activity in Staph. aureus in the mouse (mg/kg) infection Substance p.O. s.c.
Ciprofloxacin Example 27 Example 29A Example 31 Example 33 Example 35 80 10 5 10 10 2.5 aro o a :r os o o 64 0 01*0 o B D o So a a 6 0 a u i The compounds according to the invention, compared to known structurally similar compounds, show an improved antibacterial action, in particular with anaerobic microorganisms.
O
Component according to the invention as in Example 2B: A
CH
3 R disclosed in EP-A-0,350,733: B Ciprofloxacin C Le A 28 100 35 :-u
I
Table Compound ~Spec ies Strain A B C Bacteroides ES 25 0.25 1 81 fragilis DSM 2151 0.25 0.5 4 Clostridium 1024027 0.125 0.5 perfringens Bact. DSM 2079 0.5 2 8 chet aiotaomi cron (MIC values in Ag/ml; agar dilution test in the multipoint inoculator (Denley); isosensitest agar).
Preparation of the precursors Example A rSS1-2,8-Diazabicyclor4.3.Olnonane
H
HH
NH
1) [S,S]-8-Benzyl-2,8-diazab2Lcyclo[4.3.0]nonane Method I: a) Separation of the diastereonieric salts:
I
ii 7 444(11 4
III:
1 1 till It I
(III
Le A 28 100 36 g (20 mmol) of D-(-)-tartaric acid are dissolved in 10 ml of di ethylformamide by heating to 80°C and the solution is treated with a solution of 2.16 g mmol) of cis-8-benzyl-2,8-diazabicyclo[4.3.0]nonane in 3 ml of dimethylformamide. The mixture is stirred at 0°C for 1 hour, and the product is filtered off with suction and washed with dimethylformamide and methoxyethanol.
Yield: 1.93 g, Melting point: 146-151 0
C,
=-19.3 1, H 2 0).
Diastereomerically pure [S,S]-8-benzyl-2,8diazabicyclo[4.3.0]nonane D-tartrate is obtained by a single recrystallisation from methoxyethanol.
[a]23 -22.7° (c 1, H 2 0).
Melting point: 148-154°C.
b) Liberation cF the base: gof [S,S[-8-benzyl-2,8-diazabicyclo[4.3.0]nonane D-tartrate are dissolved in 250 ml of water and treated with 32 g of 45 strength sodium hydroxide solution. The precipitated oil is taken up in 150 ml of tert-butyl methyl ether, the aqueous phase is o* o extracted again with 150 ml of tert-butyl methyl ether and the combined organic phases are concentrated after drying over sodium sulphate. The Le A 28 100 37residue is then distilled in vacuo.
Yield: 18.5 g of [S,S]-8-Benzyl-2,8-diazabicyclo- [4.3.0]nonane, Boiling point: 107-109 0 C/0.1 mbar, [a]4 17.30 (undiluted).
Method II: 75.0 g (0.5 mol) of L-(+)-tartaric acid are dissolved in 250 ml of dimethylformamide at 80°C and 54.1 g (0.25 mol) of cis-8-benzyl-2,8-diazabicyclo[4.3.0]nonane are added dropwise as a solution in 75 ml of dimethylformamide. The mixture is slowly cooled to 20 0 C and the crystal suspension is stirred for 1 hour. The crystals benzyl-2,8-diazabicyclo[4.3.0]nonane L-tartrate) are filtered off with suction and the filtrate is concentrated on a rotary evaporator. The residue is dissolved in 500 ml of water and worked up as described in Method I using 63 g of 45 strength sodium hydroxide solution.
Yield: 25.2 g of [S,S]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane; the product contains 3.6 of the R,R-enantiomer (determined by gas chromatography after derivatisation with menthyl chloroformate).
iThe compound can be reacted with D-(-)-tartaric acid The compound can be reacted with D-(-)-tartaric acid 4 iiu Le A 28 100 38 r:
_,I
according to MetIbju I to give diastereomerica.ly pure [S,S]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane D-tartrate.
Recrystallisation in this case is not necessary.
Method III: 73.6 g (0.34 mol) of cis-8-benzyl-2,8-diazabicyclo- [4.3.0]nonane are added dropwise at 80 to 90*C as a solution in 111l ml of dimethylformamide to a solution of 102.9 g (0.685 mol) of L(+)-tartaric acid in 343 ml of dimethylformamide. The mixture is seeded with benzyl-2,8-diazabicyclor4.3.0]nonane L-tartrate and slowly cooled to an internal temperature of 18 0 C. The crystals are filtered off with suction, and the filtrate is seeded with [S,S]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane L-tartrate and stirred until it has crystallised completely. (After concentration and liberation of the base as described in Method I, [S,S]-8-benzyl-2,8diazabicyclo 4.3. 0 ]nonane D-tartrate can be obtained f rom the mother liquor by purification with D-tartaric acid).
The product is then filtered off with suction, washed V4,20 with dimethylfornaxide and isopropanol and dried in air.
The crystals are recrystallised from 86' strength ethanol. 52 g of [S,S]-8-benzyl-?4,B-Jiazabicyclo[4.3.0]nonane L-tartrate trihydrate are z-btained.
Melting point: 201-204 0
C,
=D +5.20 (c 1, 0444 The salt can be processed as described in Method I Le A 28 100 39 (liberation of the base) to give enantiomerically pure [S,S]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane.
Method IV: a) Separation of enantiomers of cis-8-benzyl-7,9-dioxo- 2,8-diazabicyclo[4.3.0]nonane to give [1S,6R]-8benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane.
The procedure is analogous to Example B (Method II/a), using D-(-)-tartaric acid as the chiral auxiliary reagent, or the procedure is as follows: Mother liquor and washing liquor from [1R,6S]-8benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane Ltartrate (from Example B, Method II/a) are concentrated together, the residue is taken up in water and the solution is extracted three times with 15 toluene. The toluene phases are discarded. The aqueous phase is treated with saturated sodium 44 hydrogen carbonate solution until a pH of 7 to 8 is obtained, then extracted four times with methylene chloride. The combined methylene chloride phases are 20 dried over magnesium sulphate and concentrated.
0* 96 Yield: 14.4 g (60 of theory of the originally employed racemic cis-8-benzyl-7,9-dioxo-2,8-diaza- 4 bicyclo[4.3.0]nonane).
[a] 3 (c 5, ethanol).
-D*
ta' m Le A 28 100 40 r These 14.4 g (59 mmol) are crystallised from 120 ml lei of ethanol analogously to Example B (Method II/a) using 8.6 g (57 mrnol) of D-(-)-tartaric acid.
If Yield: 8.9 g (77 of theory) of [lS,6R]-8-benzyl- 7, 9-dioxo-2, 8-diazabicyclo[4 0]nonane D-tartrate.
-46.2* (c 0.5, 1N HCl); I after recrystallisation from an ethanol/glycol monomethyl ether mixture a further purification is carried out: [aj]3 (c 0.5, 1N HCl).
g (12.7 nimol) of the diastereomerically pure tartrate obtained in this manner were converted, as described in Example B, Method Il/a, into the free_ amine: Yield: 3.0 g (96 of theory) of [lS,6R]-8-benzyl- 7, 9-dioxo-2, 8-diazabicyclo nonane, Melting point: 60-61*C, [a]23D (c 5, ethanol).
An enantiomer excess of 96.6 ee was determined by gas chromatography after derivatisation with menthyl chloroformate.
a* ab) Reductionof [lS,6R]-8--benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane to [S,S]-8-benzyl-2,8-diazabicyclo[4 Le A28 100 -41- The procedure is analogous to Example B (Method II, [lS,6R]-8-benzyl-7,9-dioxo-2,8-diazabicyclo- [4.3.0]nonane being, however, employed as the starting material.
The crude product obtained after working up proved to be [S,S]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane on derivatisation with menthyl chloroformate.
Racemisation was thus observed during the reduction.
2) [S,S]-2,8-Diazabicyclo[4.3.0]nonane 28.4 g (0.131 mol) of [S,S]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane are hydrogenated at 90"C and bar in the course of 5 hours over 5.8 g of palladium on active carbon in 190 ml of methanol. The catalyst is then filtered off with suction and 15 washed with methanol, and the filtrate is concentrated on a rotary evaporator. The residue is distilled without fractionation.
Yield: 15.0 g (90.5 of theory) of diazabicyclo[4.3.0]nonane, 20 Boiling point: 44-59"C/0.18 mbar, S' []22 -2.29° (undiluted), ee 99 (determined by gas chromatography after derivatisation with Mosher's reagent).
Method V: 3.75 g (25 mmol) of L-(+)-tartaric acid are Le A 28 100 42initially introduced in solution in 50 ml of dimethylformamide at 80°C and 10.82 g (50 mmol) of cis-8-benzyl-2,8-diazabicyclo[4.3.0]nonane are added dropwise as a solution in 15 ml of dimethylformamide.
The mixture is seeded with [R,R]-8-benzyl-2,8-diazabicyclo[4.3.0]-nonane L-tartrate and stirred for one hour at about 72°C to complete seed crystal formation.
This is then slowly cooled to 15"C, and the crystals are filtered off with suction and washed twice with 13 ml of dimethylformamide in each case. The combined filtrates are heated to 80"C and treated with a further 3.75 g (25 mmol) of L-(+)-tartaric acid. The mixture is additionally heated to 119°C until a clear solution is formed, and again slowly cooled to room temperature with seeding with 8-benzyl-2,8-diazabicyclo[4.3.0]-nonane L-tartrate.
The crystals are filtered off with suction, washed successively with dimethyl-formamide, 2-methoxyethanol and ethanol and dried in air.
Yield: 9.59 g Melting point: 188 to 192°C.
The crystals are recrystallised from 95 ml of 80 strength ethanol. 8.00 g of [S,S]-8-benzyl-2,8- .diazabicyclo[4.3.0]nonaneL-tartratetrihydrate (76 j 25 of theory) are obtained which melts at 112 to 118 0
C
with foaming, then resolidifies and melts again at 199 to 201 0
C.
4.5° (c 1, water).
ee: 98.0 (determined by gas chromatography after derivatisation with menthyl Le A 28 100 43 Le A 28 100 43- I chioroformate).
Example B fRRl-2,.8-Diazabicyclor4 .3.0 nonane
AH
H
H
NH
H
1) [R,R]-8-Benzyl-2,8-diazabicyclo[4.3.0]nonane Method I: The crystals of [R,R]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane obtained according to Example A, Method II (49.2 g) are washed with dimethylfornaxide andmethoxyethanol and recrystallised from 300 ml of methoxyethanol. 45.6 g of enantiomerically pure benzyl-2,8-diazabicyclo[4 0]nonane L-tartrate are obtained (enantiomer purity determined by gas chromatography after derivatisation with menthyl chloroformate).
Melting point: 121-124'C, [Q23 +22.30 (c 1, 1120) The salt (44.5 g) is converted into the free base as described in Example A, Method lb. 20.2 g of benzyl-2,8-diazabicyclo[4.3.0]nonane are obtained.
Boiling point: 107-111 0 C/0.04 mbar, Le A28 100 44.
[a]4 -17.5° (undiluted).
Method II a) Separation of enantiomers of cis-8-benzyl-7,9-dioxo- 2,8-diazabicyclo[4.3.0]nonane to give [1R,6S]-8benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane 24.1 g (98.8 mmol) of cis-8-benzyl-7,9-dioxo-2,8diazabicyclo[4.3.0]nonane are heated to reflux with stirring in a mixture of 410 ml of ethanol and 25 ml of acetonitrile in a three-necked flask. 14.8 g (98.8 mmol) of L-(+)-tartaric acid are then added at once. After all the tartaric acid has completely dissolved, the heating is first turned off, but the flask is left in the oil bath. When the system has cooled until the solution no longer boils, the stirrer is turned off. Crystallisation and addition of seed crystals takes place at a temperature of 0 C. After standing overnight and cooling to room temperature, the precipitated crystals are filtered tt off with suction and washed with a little ethanol/petroleum ether and dried at 80°C for 2 hours.
Yield: 9.8 g (50 of theory) of [lR,6S]-8-benzyl- 7,9-dioxo-2, 8-diazabicyclo [4.3.0 ]nonane L-tartrate, [a] 3 +47.70 (c 0.5, IN HC1).
The compound can be further purified by Le A 28 100 p recrystallising twice from a mixture of ethanol and glycol monomethyl ether: [a]D 3 +58.6" (c 0.5, IN HC1).
1 H-NMR (DMSO): 7.22-7.35 (27, 2H, aryl-H); 4.55 (s, 2H, benzyl-CH 2 4.28 2H, tartaric acid-CH); 3.91 1H, 1-CH); 2.97 (dd, 1H, 6-CH); 2.53-2.66 (m, 2H, 3-cH2); 1.78 and 1.68 (2m, 2H, 5-CHz); 1.42 and 1.28 ppm (2m, 2H, 4-CH 2 CzsH 2 zN 2 0s(394) Calculated: C 54.4 H 5.6 N 7.1 J 32.5 Found: C 54.7 H 5.8 N 7.1 0 32.4 The determination of the absolute configuration was carried out by means of an X-ray structural analysis:
H
SH HO C0 2
H
N HO" COH H 0 3.6 g (9.1 mmol) of the diastereomerically pure tartrate obtained in this manner are dissolved in water to liberate the base and treated with saturated sodium hydrogen carbonate solution until a pH of 7 to 8 is obtained. The aqueous solution is i 20 extracted four times with 20 ml of methylene chloride each time. The combined methylene chloride phases are dried over magnesium sulphate and '"y Le A 28 100 46 t.
concentrated.
Yield 2.2 g (99 of theory) of [lR,6S]-8-benzyl- 7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane Melting point: 60-61"C, [a] 3 +21.8" (c 5, ethanol).
An enantiomer excess of 93.8 ee was determined by gas chromatography after derivatisation with menthyl U chloroformate.
I b) Reduction of [1R,6S]-8-benzyl-7,9-dioxo-2,8diazabicyclo[4.3.0]nonane to [R,R]-8-benzyl-2,8diazabicyclo[4.3.0]nonane In a heated flask, 0.34 g (9 mmol) of lithium i aluminium hydride is introduced under N 2 in 18 ml of anhydrous tetrahydrofuran and 0.73 g (3 mmol) of [1R,6S]-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane is added dropwise as a solution in 3 ml of anhydrous tetrahydrofuran. The mixture is then boiled for 16 hours with reflux condensation.
Working up is carried out by dropwise edition of 0.34 ml of water in 10 ml of tetrahydrofuran, S0.34 ml of 10 strength sodium hydroxide solution and 1.02 ml of water. The precipitate is filtered off with suction and washed with tetrahydrofuran, and the filtrate is concentrated. 0.7 g of crude [R,R]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane remains >1 (GC purity: 99 Le A 28 100 47 L .P It was not possible to determine any racemisation during the gas chromnatographic determination of the enantiomer purity using menthyl chioroformate.
2) [R,R]-2,8-diazabicyclo[4.3.0]nonane 19.4 g (0.09 mol) of [R,R]-8-benzyl-2,8-diazabicyclo[4.3.0]nonane are hydrogenated according to the procedure of Example A, 2.
Yield: 9.61 g (85 of [R,R]-2,8-diazabicyclononane, Boiling point: 45-58OC/0.08 mbar, []23D +2.30' (undiluted).
Example C rS ,Si -2-Methyl-2,.8-diazabicvclo F4.3.0 ilonane
CH
3
IH
N. :NH
H
1) [S,S]-8-Benzyl-2-methyl-2,8-diazabicyclo[4.3.0]nonane 43.2 g (0.2 mmol) of [S,S]-8-benzyl-2,8-diazabi-.
cyclo[4.3.0]nonane are treated with 20 ml of 37% formaldehyde solution, 40 ml of water and 24 g of acetic acid and the mixture is hydrogenated over Le A28 100-48- 2 g of palladium on active carbon (5 at 20"C and bar for 10 hours. The catalyst is then filtered off with suction, the filtrate is rendered alkaline with potassium carbonate and the product is extracted with tert-butyl methyl ether. After drying over sodium sulphate, the mixture is concentrated and the residue is distilled in vacuo.
Yield: 14.8 g, Boiling point: 114-124°C/0.14 mbar.
2) [S,S]-2-Methyl-2,8-diazabicyclo[4.3.0]nonane 12.9 g (56 mmol) of [S,S]-8-benzyl-2-methyl-2,8diazabicyclo[4.3.0]nonane are hydrogenated over 1.1 g of palladium on active carbon (5 at and 90 bar in 90 ml of methanol. The mixture is then filtered, the filtrate is concentrated on a rotary evaporator and the residue is distilled in vacuo.
Yield: 5.5 g of enantiomerically pure o4, methyl-2,8-diazabicyclo[4.3.0]nonane (detection by derivatisation with Mosher's reagent), Boiling point: 78-81 0 C/14 mbar.
Le A 28 100 49 Le A 28 100 49 i F A L L~ I ii ~C
TI
It
B
it
I
ExaMple D rR,Rl-2-Methyl-2,8-diazabicyclor4.3.Olnonane
CH
3
NH
H
The compound is prepared by the working instructions described in Example C, starting from 43.2 g (0.2 mol) of [R,R]-8-benzyl-2,8--diazabicyclo(4.3.0]nonane.
Yield: 4.9 g of [R,R]-2-methyl-2,8-diazabicyclo[4.3.0]nonane.
Boiling point: 30-33*C/O.12 mbar.
Example E cis-7 ,9-Dioxo-r-- (r Sl1-1-phenvl-ethyl-) -2,8diazabicyclo[F4 .3 01nonane 0 N -CH- Ph
N
0 CH 3 1) N- ([lS]-1-Phenyl-ethyl)pyridine-2 ,3-dicarboximide 74.5 g (0.5 mol) of pyridine-2,3-dicarboxylic anhydride are initially introduced at 20*C in 15 solution in 500 ml of dioxane and 60.5 g (0.5 mol)
II
I I
III,
C, II
I
4 Le A 28 100 50
K
of S-(-)-l-phenyl-ethylamine are added dropwise, whereupon the temperature rises to 33"C. The mixture is stirred for a further 1 hour and then concentrated on a rotary evaporator, and residual solvent is removed at 40°C/0.1 mbar. The residue is taken up in 245 g (2.4 mol) of austic anhydride, and the solution is treated with 4.9 g (0.06 mol) of anhydrous sodium acetate and stirred at 100"C for 1 hour. After cooling, the mixt-'re is poured onto 1 1 of ice-water while stirring well, and the precipitate is filtered off with suction, washed with cold water and hexane and dried in air.
The crude product (114 g, Melting point: 112-114 0
C)
is recrystallised from 285 ml of methanol.
Yield: 96.3 g (76 Melting point: 115-117 0
C,
[a]2 -46.90 (c 2, ethanol).
2) cis-7,9-Dioxo-8-([1S]-1-phenyl-ethyl)-2,8diazabicyclo[4.3.0]nonane 79.7 g (0.316 mol) of N-([1S]-l-phenylethyl)pyridine-2,3-dicarboximide are hydrogenated over g of palladium on active carbon (5 strength) at 90°C/100 bar in 600 ml of tetrahydrofuran. The catalyst is filtered off after completion of the absorption of hydrogen and the filtrate is completely concentrated. 83.7 g of a viscose residue are obtained.
V
Le A 28 100 51 P -i Purity: 95 strength, H-NMR (CDC1 3 200 MHz): 1.4-1.7 3H); 1.82 and 1.83 (2d, 3H); 1.9-2.05 1H); 2.28 (broad s, 1H); 2.54-2.86 3H); 3.77 1H); 5.39 1H); 7.24- 7.48 ppm Example F cis-2-Oxa-5,8-diazabicyclof4.3.0]nonane
H
N cis C 12NH 1) trans-l-Benzoyl-3-bromo-4-(2-hydroxyethoxy)pyrrolidine 4*44i 95 g (0.55 mol) of l-benzoyl-3-pyrroline are dissolved in 380 g of ethylene glycol and 101 g (0.57 mol) of N-bromosuccinimide are added in 5 g portions in the course of 2 hours. The mixture is then stirred overnight at room temperature, poured into water and extracted with methylene chloride, Sand the solution is dried over magnesium sulphate and concentrated. The residue (188 g) was chromatographed on silica gel using ethyl acetate.
e Yield: 136.5 g (78 of theory), Purity by GC: 99 Le A 28 100 52 LeA 28 100 52r ,1 ~C Ui -'r L -II I 2) trans-l-Benzoyl-3-bromo-4-(2-tosyloxyethoxy)pyrrolidine 92 g (0.239 mol) of trans-l-benzoyl-3-bromo-4-(2hydroxyethoxy)-pyrrolidine, 32 g (0.316 mol) of triethylamine and 1 g of 4-dimethylaminopyridine are dissolved in 750 ml of toluene and 60 g (0.31 mol) of tosyl chloride in 450 ml of toluene are added dropwise. The mixture is stirred at room temperature for two days, water is added, and the aqueous phase is separated off and extracted with toluene. The toluene solutions are washed with 10 strength hydrochloric acid, dried over magnesium sulphate and concentrated, the residue is dissolved in ethyl acetate and the solution is filtered through silica 15 gel. The filtrate is concentrated.
I Yield: 125 g (91 of theory).
The thin layer chromatogram shows a homogeneous compound.
3) cis-8-Benzoyl-5-benzyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane S124 g (0.265 mol) of trans-l-benzoyl-3-bromo-4-(2tosyloxyethoxy)-pyrrolidine are heated under reflux overnight with 86 g (0.8 mol) of benzylamine in 1 of xylene, the salts of benzylamine are filtered off with suction and the filtrate is concentrated.
Le A 28 100 53- L Crude yield: 91.2 g.
4) cis-5-Benzyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane 91 g (0.265 mol) of cis-8-benzoyl-5-benzyl-2-oxa- 5,8-diazabicyclo[4.3.0]nonane are heated under reflux overnight with 200 ml of concentrated hydrochloric acid and 140 ml of water. After cooling, the benzoic acid is filtered off with suction, the filtrate is concentrated to half the volume, the solution is rendered alkaline with potassium carbonte and extracted with chloroform, the extract is dried over potassium carbonate and concentrated, and the residue is distilled.
i .Yield: 30.7 g (48.8 of theory), Boiling point: 134-142°C/0.6 mbar, Purity by GC: 92 cis-2-0xa-5,8-diazabicyclo[4.3.0]nonane dihydrochloride 26 g (0.11 mol, 92 strength) of cis-5-benzyl-2oxa-5,8-diazabicyclo[4.3.0]nonane in 180 ml of ethanol and 19 ml of concentrated hydrochloric acid are hydrogenated in 3 g of palladium/active carbon (10 Pd) at 100 C and 100 bar. The catalyst is filtered off with suction, the filtrate is concentrated and the separated crystals are dried in a dessicator over phosphorus pentoxide.
Le A 28 100 54-
I
D
Yield: 17.1 g (77 of theory), Melting point: 244-250"C.
Example G Separation of enantiomers of cis-5-benzyl-2-oxa-5,8diazabicyclo[4.3.0]nonane 150.1 g (1 mol) of D-(-)-tartaric acid are initially introduced into 700 ml of methanol at 60 to 65"C and 218.3 g (1 mol) of cis-5-benzyl-2-oxa-5,8-diazabicyclo- [4.3.0]nonane are added dropwise as a solution in 300 ml 10 of methanol. The mixture is then slowly allowed to cool o" to about 49"C until the solution becomes cloudy, and is seeded with crystals of 1R,6S-5-benzyl-2-oxa-5,8-diaza- °o bicyclo[4.3.0]nonane D-tartrate obtained in a prior ex- 00 aperiment, stirred for 30 minutes at this temperature for seed crystal formation and then slowly cooled down to 0 to 3°C. After filtering off with suction, the solid is 4. ewashed with a mixture of 200 ml of ethanol and 100 ml of .'methanol cooled to 0°C and then 3 times with 300 ml of ethanol in each case and the product is then dried in 0* t 20 air.
Yield: 160.3 g of 1R,6S-5-benzyl-2-oxa-5,8-diazabicyclo- [4.3.0]nonane tartrate (87 of theory) Melting point: 174.5 to 176.5°C ee 97 (after derivatisation with 1-phenyl-ethyl 25 isocyanate and HPLC analysis).
Le A 28 100 55 i i. ~e C 23 [a]D +24.0" (c 1, methanol).
156.9 g of the 1st crystallisate are recrystallised from 1,500 ml of methanol.
Yield: 140.0 g (89 recovered) Melting point: 176 to 177°C +25.2" (c 1, methanol).
The methanolic mother liquor from the 1st crystallisation is concentrated on a rotary evaporator. The syrupy residue (236 g) is dissolved in 500 ml of water, adjusted to pH 12 to 13 with 250 ml of 6N sodium hydroxide solution, extracted 3 times with 350 ml of toluene each time, and the extracts are dried over sodium carbonate and concentrated in vacuo. The residue, 113.1 g of a brown oil which, according to gas chromatographic investigation, contains 97 of cis-5-benzyl-2-oxa-5,8diazabicyclo[4.3.0]i 1 onane, is employed without purification for the preparation of the 1S,6R-enantiomer.
113.1 g (0.518 mol) of crude concentrated 1S,6R-5-benzyl- 2-oxa-5,8-diazabicyclo[4.3.0]nonane are dissolved in 155 ml of methanol and added dropwise to a boiling *solution of 77.8 g (0.518 mol) of L-(+)-tartaric acid in 363 ml of methanol. A crystal magma is gradually formed ,during the dropwise addition. The mixture is stirred at o 60°C for 1 hour and then slowly cooled to 0°C in the course of 2 hours. The crystals are filtered off with suction and washed with a 2:1 mixture of ethanol and methanol cooled to 0°C and then 3 times with ethanol. The Le A 28 100 56-
S'
SI
product is then dried in air.
Yield: 145.5 g of 1S,6R-5-benzyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane L-tartrate (79 of theory) Melting point: 174.5 to 176.5°C ee 97 (after derivatisation with 1-phenyl-ethyl isocyanate and HPLC analysis) [a]3 -24.0° (c 1, methanol).
Liberation of the enantiomerically pure bases: 144 g (0.39 mol) of 1S,6R-5-benzyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane tartrate are dissolved in 250 ml of water and 175 ml (1.05 mol) of 6 N sodium hydroxide solution are added. The deposited oil is taken up in 500 ml of toluene, the organic phase is separated off and the aqueous phase is extracted a further 3 times with 250 ml of toluene in each case. The combined organic phases are dried over sodium carbonate, filtered and concentrated on a rotary evaporator. The residue is distilled through a cm Vigreux column under a high vacuum.
Yield: 81.6 g (96 of theory) of 1S,6R-5-benzyl-2-oxa- 5,8-diazabicyclo[4.3.0]nonane Boiling point: 120 to 139 0 C/0.04 to 0.07 mbar Purity: 100 determined by gas chromatography Density: 6 1.113 g/ml i -60.9" (undiluted).
25 Distillation residue: 0.12 g In the same manner, 76.0 g (93 of theory) of 1R,6S-5benzyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane are obtained from 139.2 g (0.376 mol) of IR,6S-5-benzyl-2-oxa-5,8diazabicyclo[4.3.0]nonane tartrate.
Le A 28 100 57 L [a]3 +61.20 (undiluted).
The separation of enantiomers described for 2-oxa-5,8-diazabicyclo[4.3.0]nonane can also be carried out analogously with trans-5-benzyl-2-oxa-5,8diazabicyclo[4.3.0]nonane to give R,R- and 2-oxa-5,8-diazabicyclo[4.3.0]nonane.
Example H 1) tert-Butyl 3S,4S-4-allyloxy-3-hydroxypyrrolidine-lcarboxylate
S
10 16.5 g (0.55 mol) of 80 strength NaH are initially introduced into 500 ml of absolute dioxane and a solution of 107.5 g (0.53 mol) of tert-butyl S,S- 3,4-dihydroxypyrrolidine-l-carboxylate (DE-A-3,403,194) dissolved hot in absolute dioxane is added dropwise at 60°C. The mixture is stirred at for 1 hour and 64 g (0.53 mol) of allyl bromide are then added dropwise. The mixture is then stirred at 60°C for three hours. It is concentrated and the residue is dissolved in 200 ml of water and 600 ml of methanol. The solution is extracted three times with 200 ml of pentane each time, the methanol is stripped off on a rotary evaporator, the residue is diluted with 200 ml of water and the mixture is extracted with methylene chloride. The methylene chloride solution is dried over MgSO, and concentrated, and the residue is dissolved in Le A 28 100 58j,.(P tert-butyl methyl ether (200 ml). 9 g of starting material (44 mmol) crystallised out overnight. The ether solution is concentrated and distilled.
Yield: 83 g (80 of theory relative to recovered starting material and diallyl ether) Boiling point: 149°C/0.7 mbar to 159 0 C/0.9 mbar.
The distillate contains 5 of the starting material and 4 of diallyl ether.
The pentane extract yielded 17 g of a mixture of j 10 15 desired product and 84 of diallyl ether.
[a]D3 -10.5° (c 1, methanol).
2) tert-Butyl 3S,4S-3-hydroxy-4-(2-hydroxyethoxy)pyrrolidine-l-carboxylate S64 g (0.24 mol, 91 strength) of tert-butyl 3S,4S- 4-allyloxy-3-hydroxypyrrolidine-l-carboxylate are dissolved in 250 ml of methanol and cooled to 0°C, and ozone is passed through the solution until a washing bottle containing potassium iodide solution and connected in series indicates the emergence of ozone and thus complete reaction. Residues of ozone are carried out by means of a stream of nitrogen, then the resulting ozonide is reduced at 0°C using 18 g of sodium borohydride, which is added in 1 g portions. The mixture is then stirred overnight at room temperature and concentrated, the residue is diluted with water, and the mixture is treated with Le A 28 100 59- .1 i- r
I
1o 00 0 0 0O 0 0 g of potassium carbonate and extracted five times with 100 ml of methylene chloride each time. The organic solutions are dried over magnesium sulphate and concentrated.
Yield: 65.8 g (100 of theory) The product is 91 strength by gas chromatography.
-15.2° (c 0.97, methanol).
3) 3S,4S-l-tert-Butoxycarbonyl-3-tosyloxy-4-(2tosyloxyethoxy)-pyrrolidine 2.7 g (10 mmol, 91 strength) of tert-butyl 3S,4S- 3-hydroxy-4-(2-hydroxyethoxy)-pyrrolidine-lcarboxylate are initially introduced into 30 ml of methylene chloride, 6 ml of 45 strength sodium hydroxide solution and 0.1 g of benzyltriethylammonium chloride are added and a solution of 2.86 g mmol) of tosyl chloride in 10 ml of methylene chloride are then added dropwise with cooling. The mixture is then stirred for a further hour at room temperature and poured into 20 ml of water, the organic phase is separated off and the aqueous phase is extracted with methylene chloride. The organic phases are dried over magnesium sulphate and concentrated.
Yield: 5 g (90 of theory).
The product is homogenous by thin layer chromatography.
o o o o 0 606 0 o0 o a a e ii Le A 28 100 60 L c 4) tert-Butyl 1S,6R-5-benzyl-2-oxa-5,8-diazabicyclo- [4.3.0]nonane-8-carboxylate 87 g (156 mmol) of .S,4S-l-tert-butoxycarbonyl-3tosyloxy-4-( 2-tosyloxyethoxy) -pyrrolidine are heated under reflux overnight with 58 g (0.54 mol) of benzylamine in 1 1 of xylene. The mixture is cooled, precipitated salts of benzylamine are filtered off with suction and the residue is concentrated.
Yield: 43 g (58 of theory).
The product is 67 strength by gas chromatography.
5) 1S,6R-5-Benzyl-2-oxa-5,8-diazabicyclo[4,3.0]nonane o° 43 g (90 mmol) of tert-butyl IS,6R-5-benzyl-2-oxa- 0:8" 5,8-diazabicyclo[4.3.0]nonane-8-carboxylate are heated under reflux in 35 ml of concentrated hydrochloric acid and 35 ml of water until the evolution of carbon dioxide is complete. The mixture is rendered alkaline with potassium carbonate and extracted with chloroform, the organic solutions are dried over MgS04 and concentrated, and the residue is 20 distilled twice through a 20 cm Vigreux column.
Yield: 11.1 g (55 of theory) S' Boiling point: 108 115°C/0.07 mbar [a]D 6 -58.30 (undiluted).
Le A 28 100 61 .i I Example I 1) tert-Butyl 3R, 4R-4-allyloxy-3-hydroxypyrrolidine-lcarboxylate The reaction is carried out analogously to Example Hi) using tert-butyl R,R-3,4-dihydroxypyrrolidine- 1-c arboxylate: Boiling point: 145 0 C/0.1 mbar +9.50 (c 1.0, methanol).
The product is 95 strength by gas chromatography.
2) tert-Butyl 3R,4R-3-hydroxy-4-(2-hydroxyethoxy)pyrrolidine-1-carboxylate The reaction is carried out analogously to Example H2) using tert-buty. 3R,4R-4-allyloxy-3-hydroxypyrrolidine-1-carboxylate: Yield: 99 of theory (0.175 molar batch) []20 +16.50 (c 0.94, methanol).
3) 3R,4R-1-tert-Butoxycarbonyl-3-tosyloxy-4-(2tosyloxyethoxy) -pyrrolidine The reaction is carried out analogously to Example H3) using tert-butyl 3R,4R-3-hydroxy-4-(2hydroxyethoxy) -pyrrolidine-1-carb-oxylate Yield: quantitative (0.11 molar batch).
4) tert-Butyl 1R,6S-5-benzyl-2-oxa-5,8- (.iazabicyclo 3.0] nonane-.8-carboxylate Le A28 100 62- The reaction is carried out analogously to Example H4) using 3R,4R-l-tert-butoxy-carbonyl-3-tosyloxy- 4-(2-tosyloxyethoxy)-pyrrolidine: Yield: 40 of theory molar batch).
5) 1R,6S-5-Benzyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane The reaction is carried out analogously to Example using tert-butyl 1R,6S-5-benzyl-2-oxa-5,8diazabicyclo[4.3.0]nonane-8.-carboxylate: Yield: 63 of theory (40 mmolar batch) Boiling point: 120°C/0.06 mbar The product is 95 strength by gas chromatography [a]3 +58.50 (undiluted).
Example J 1) IS,6R-2-Oxa-5,8-diazabicyclo[4.3. 0]nonane 15 dihydrochloride t g (34.4 mmol) of 1S,6R-5-benzyl-2-oxa-5,8diazabicyclo[4.3.0]nonane are hydrogenated at 100°C and 100 bar on 1 g of palladium/active carbon (10 Pd) in 200 ml of ethanol with the addition of 7 ml of concentrated hydrochloric acid. The catalyst is filtered off with suction and washed several times with water. The aqueous filtrate is concentrated, whereupon the residue crystallises. The crystals are thoroughly saturated with ethanol, filtered off with suction and dried in air.
Le A 28 100 63 L i i i Yield: 4.6 g (66.5 of theory) Melting point: 233-235 0
C.
2) lS,6R-2-Oxa-5,8-diazabicyclo[4.3.0]nonane 59 g (0.27 mol) of 1S, 6R-5-benzyl-2-oxa-5,8diazabicyclo[4.3.0]nonane are hydrogenated at 120 0
C
and 120 bar on 5 g of pall adium/ active carbon (10 Pd) in 500 ml of ethanol. The catalyst is filtered of f with suction, the filtrate is concentrated and the residue is distilled.
Yield: 32.9 g (95 of theory) L. Boiling point: 65*C/0.03 mbar Rotation 28 =+82 Rotaio 8.2 (undiluted).
ee value: -2 99.5 (by derivatisation with Mosher reagent).
Example K 1 1) lR, 6 S 2 -Ox a-5 8 -,ia za b ic yc 1o [4.3 .0 ]n on ane dihydrochloride The reaction is carried out analogously to Example J1) using 1R, 6S-5-benzyl-2-oxa-5, 8-diazabicyclo- [4.3.0]nonane: Yield: 77 of theory (23.8 mmolar batch) Melting point: 230-232 0
C.
2) IR,6S-2-Oxa-5,8-diazabicyclo[4.3.0]nonane Le A28l100 -64
U
Le A 28 100 -51 The reaction is carried out analogously to Example J2) using 1R,6S-5-benzyl-2-oxa-5,8-diazabicyclo- [4.3.0]nonane: Yield: 93.3 of theory (1.58 molar batch) Boiling point: 63 65*C/0.03 mbar Ro %ation: -8.40 (undiluted).
ee value: i 99.5 (by derivatisation with Mosher reagent).
1R,6R- or 1S,6S-2-0xa-5,8-diazabicyclo[4.3.0]nonane can be obtained analogously.
K Example L 1R,6S-2-Oxa-5,8-diazabicyclo[4.3.0]nonane dihydrobromide 1) 1T,6S-5-(1R-Phenylethyl)-8-tosyl-2-oxa-5,8-diaza- 15 It(yclo[4.3.0]nonane 101.8 g (0.196 mol) of trans-3-brom-1-tosyl-4-(2tosyloxyethoxy)-pyrrolidine and 72 g (0.584 mol) of R-(+)-1-phenylethylamine in 900 ml of xylene are heated under reflux overnight. The cooled solution is washed with 2N sodium hydroxide solution and dried over potassium carbonate, the drying agent is removed and the solvent is concentrated. On cooling, crystals are deposited from the residue which are filtered off with suction and recrystallised from a mixture of 750 ml of petroleun ether and 200 ml of Le A 28 100 .f n-butanol.
Yield: 15 g (39.6 of theory of optically pure material.
Melting point: 188"C, Rotation 8 +103.7" (c 1, CHCl 3 2) 1R,6S-8-Tosyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane 13 g (33.6 mmol) of 1R,6S-5-(iR-phenylethyl)-8tosyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane are hydrogenated at 100 0 C and 100 bar on 2.5 g of palladium/ active carbon (10 Pd) in 200 ml of ethanol. The 0 catalyst is filtered off with suction, the filtrate is concentrated and the residue is recrystallised from 30 ml of toluene.
Yield: 7.5 g (79 of theory), S"o 15 Melting point: 160-161 0
C,
Rotation: [a]2 3 +17.50 (c 1.21, CHCl 3 3) 1R,6S-2-Oxa-5,8-diazabicyclo[4.3.0]nonane dihydrobromide 7 g (24.8 mmol) of 1R,6S-8-tosyl-2-oxa-5,8-diazabicyclo[4.3.0]nonane are dissolved in 25 ml of 33 strength hydrogen bromide solution in glacial acetic acid, 5 g of phenol are added and the mixture is stirred overnight at room temperature. It is diluted with diisopropyl ether, and the crystallised salt is filtered off with suction and dried in air.
Yield: 5.5 g.
Le A 28 100 66- L .r i f: Derivatisation with Mosher reagent and gas chromatographic analysis shows only one detectable enantiomer (ee 99.5 Example M 5-Bromo-l-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo- 3-quinolinecarboxylic acid Br O F COOH F
A
FN
1) 2-Bromo-3,4,5,6-tetrafluoro-benzoyl chloride 365 g (1.33 mol) of 2-bromo-3,4,5,6-tetrafluorobenzoic acid [Tetrahedron 23, 4719 (1967)] are .0 introduced into 2 1 of thionyl chloride and the mixture is heated uncj r reflux for 11 hours until the evolution of gas stops. Excess thionyl chloride is stripped off in vacuo and the residue is distilled.
Yield: 330 g (85 of theory), Boiling point: 81-85"C/3-5 mbar.
2) Diethyl malonate (2-bromo-3,4,5,6-tetrafluoro-benzoyl)-
.I
15.9 g (0.167 mol) of magnesium chloride are Le A 28 100 67 r r introduced into 150 ml of anhydrous acetonitrile (dried over zeolite) and 26.9 g (0.167 mol) of diethyl malonate are allowed to drop in with cooling. The mixture is cooled to 0°C, 46 ml (33.7 g 0.33 mol) of triethylamine are added dropwise and the mixture is stirred for 30 minutes.
48.9 g (0.168 mol) of 2-bromo-3,4,5,6-tetrafluorobenzoyl chloride are then added dropwise, and the mixture is stirred for a further 1 hour at 0°C and brought to room temperature overnight. It is treated with 100 ml of 5 N hydrochloric acid and extracted Sthree times with methylene chloride, and the extracts are dried with Na 2
SO
4 and concentrated in vacuo.
S 15 Crude yield: 62.7 g.
3) Ethyl (2-bromo-3,4,5,6-tetrafluoro-benzoyl)-acetate g of crude diethyl (2-bromo-3,4,5,6-tetrafluorobenzoyl)-malonate are introduced into 150 ml of water and treated with 0.6 g of 4-toluenesulphonic S 20 acid, and the mixture is heated under reflux for 6 hours. It is extracted with methylene chloride, and the extract is washed with water, dried with Na 2
SO
4 and concentrated.
Crude yield: 46 g, 25 Boiling point (sample distillation in a bulb tube): 150-160°C(oven)/3 mbar; Mass spectrum: 342 297 (M+-OC 2 263 (M Br), 257, 255 (M*-CH 2
CO
2
C
2 235 (263-28).
4y Le A 28 100 68 4) Ethyl 2-(2-bromo-3,4,5,6-tetrafluoro-benzoyl)-3ethoxy-acrylate g of crude ethyl (2-bromo-3,4,5,6-tetrafluorobenzoyl)-acetate are introduced into 32.2 g (0.31 mol) of acrtic anhydride and 28.4 g (0.19 mol) of triethyl orthoformate and the mixture is heated under reflux for 2 hours. Excess reagent is first stripped off in vacuo, then under a high vacuum (bath up to 120-130°C) and the crude product is reacted to the next step.
Crude yield: 50.7 g 5) Ethyl 2-(2-bromo-3,4,5,6-tetrafluoro-benzoyl)-3cyclopropylamino-acrylate 9 t S: 50.7 g of crude product from Step 4) are treated dropwise with 8.6 g (0.15 mol) of cyclopropylamine in 90 ml of ethanol with ice-cooling, the mixture is 0 stirred at room temperature, allowed to stand overnight and again well cooled, and the crystallisate is filtered off with suction, washed with cold ethanol and dried.
Yield: 29 g (42 over 4 steps), 0 Melting point: 103-105"C (from ethanol).
6) Ethyl 5-bromo-l-cyclopropyl-6,7,8-trifluoro-l,4dihydro-4-oxo-3-quinolinecarboxylate Le A 28 100 69 t 1 28 g (68 mmol) of ethyl 2-(2-bromo-3,4,5,6tetrafluoro-benzoyl)-3-cyclopropylaminoacrylate are heated under reflux for 6 hours with 6.9 g (164 mmol) of sodium fluoride in 88 ml of DMF. The mixture is poured into water after cooling, Pnd the deposited precipitate (red) is filtered off with suction, washed with plenty of water and dried at in a recirculating air oven.
Crude yield: 27.3 g, Melting point: 150-175C; after recrystallisation from glycol monomethyl ether: Melting point: 187-191 0
C.
7) 5-Bromo-l-cyclopropyl-6,7,8-trifluoro-l,4-dihydro- 4-oxo-3-quinolinecarboxylic acid 26.7 g (68 mmol) of crude ethyl cyclopropyl-6,7,8-trifluoro-l,4-dihydro-4-oxo-3quinolinecarboxylate are introduced into a mixture of 165 ml of acetic acid, 110 ml of water and 18 ml of concentrated sulphuric acid and heated under reflux for 2 hours. The cooled reaction mixture is poured into ice-water, and the deposited precipitate is filtered off with suction, washed with plenty of 0o., water and dried in a recirculating air oven at Yield: 19.7 g (80 of theory), Melting point: 208-210"C (with decomposition); after recrystallisation from glycol monomethyl ether: Melting point: 212-214°C (with decomposition); Le A 28 100 70 1111~11~(
I:
I, '0 NMR 1 H (DMSO): 8.73 s (1H at 4,16 m (1H, cyclopropyl) 1,2 m (4H, cyclopropyl) [ppm].- Mass spectrum: 361 (M+-H 2 317 (M-C0 2 41 10 0 %1 CA11).
Preparation of the final compounds Example 1
COOH
U
0600 06
H-H
F1
I
A. 1-Cvclopropvl-7-(rS,S1-2,8-diazabicyclof4.3.Olnon-8vl) -6,.8-difluoro-1,.4-dihydro-4-oxo-3-Quinolinecarboxylic acid 141.5 g (0.5 mol) of 1-cyclopropyl-6,7,8-trifluoro-1,4dihydro-4-oxo-3-quinolinecarboxylic acid are heated under reflux for 1 hour with 69.25 g (0.55 mol) of 2,8-diazabicyclo[4.3.0]nonane (ee 99.5 GC 99.8 strength) in a mixture of 1500 ml of acetonitrile and 750 ml of diinethylforiamide in the presence of 55 g mol) of 1,4-diazabicyclo-[2.2.2]octane. The suspension is cooled, and the precipitate is filtered off with suction, washed with water and then additionally stirred with 1 1 of water (pH The product is filtered off with suction and dried at 60 0 C in a recirculating air Le A 28 100 71 oven.
Yield: 163.4 g (84 of theory), Melting point: 249-251"C (with decomposition) B. (-)-l-Cvclopropvl-7-([S,S1-2,8-diazabicycloF4.3.01non- 8-yl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride g (15.4 mmol) of l-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6,8-difluoro-l,4-dihydro-4-oxo- 0 3-quinolinecarboxylic acid are dissolved in 40 ml of 10 half-concentrated hydrochloric acid at 60°C and the solution of the hydrochloride is filtered. The filtrate is concentrated to one half, cooled in ice and treated with 40 ml of ethanol. The yellow crystallisate is filtered off with suction, washed with ethanol and dried at 60"C in a high vacuum, where the colour lightens.
5.51 g (84 of theory) of the hydrochloride are obtained, which is already very pure.
For further purification, it is dissolved in 50 ml of water in the presence of heat. The yellow solution is treated with 5 ml of half-concentrated hydrochloric acid I 2* and cooled in ice, and the deposited crystallisate is I filtered off with suction, washed well with ethanol and i dried first at room temperature and then under a high vacuum at 100"C.
25 Yield: 4.64 g (70.8 of theory), Le A 28 100 72 Melting point: 324-325'C (with decomposition), TLC (silica gel, dichloromethane /methanol/ 17 strength aqueous ammonia 30:8:1): homogeneous, Rf value: 0.3, -2560 (c 0.5, H,0), Purity (HPLC): 99.4 strength,
C
2
OH
2 1
F
2
N
3 0 3 .HCl(425.5) Calculated: C 56.4 H 5.2 N 9.9 Cl 8.3 Found: C 56.3 H 5.4 N 9.8 Cl 8.3 Example 2
COOH
H N
N
A. 8-Chloro-l-cyclopropvl-7-(rS,S1-2,8-diazabicycloa. r4.3.Olnon-8-vl)-6-fluoro-1,4-dihvdro-4-oxo-3-Quinolinecarboxylic acid 2 batches of the following size are run in parallel and worked up together: 180 g (0.6 mol) of 8-chloro-l-cyclopropyl-6,7-difluoro- 1, 4-dihyciro-4-oxo-3-quinolinecarboxylic acid are heated under reflux for 1 hour with 84 g (0.67 mol) of S 8-diazabicyclo 3. 0 nonane in a mixture of 1. 8 1 of acetonitrile/900 ml of dimethylformamide in the Le A28 100 -73- Ill^aET~LI. 1~ presence of 99 g (0.88 mol) of 1,4-diazabicyclo[2.2.2]octane (DABCO) (internal temperature: 90.5"C). The yellow solution is cooled and treated with seed crystals (obtained from a 5 ml sample which was concentrated; residue stirred with acetronitrile). The mixture is stirred for 2 hours at about 3"C, and the deposited precipitate from both batches is rapidly filtered off with suction, washed with acetronitrile and introduced into 1.5 1 of ice-water. The initially thin, wellstirrable suspension after about 10 minutes becomes a poorly stirrable mass, which is diluted with a further 150 ml of water. The precipitate is filtered off with Ssuction, washed with water and dried at 80°C in a recirculating air drying oven.
15 Yield: 402 g (82.7 of theory), faintly yellow product; Melting point: 193-196 0 C (with decomposition), R, value (silica gel; methylene chloride/methanol/17 o strength aqueous NH 3 30:8:1): 0.4.
B. 8-Chloro-l-cyclopropyl-7-( [S,S-2,8- S 20 diazabicyclo[4.3.0]non-8-yl)-6-fluoro-l,4-dihydro-4-oxo- 3-quinolinecarboxylic acid hydrochloride 13.1 g (32 mmol) of 8-chloro-l-cyclopropyl-7-([S,S]-2,8- 0 diazabicyclo[4.3.0]non-8-yl)-6-fluoro-l,4-dihydro-4-oxo- 3-quinolinecarboxylic acid are suspended in 50 ml of water and brought into solution by addition of 50 ml of half-concentrated hydrochloric acid. The mixture is filtered through a glass frit, the filtrate is Le A 28 100 74-
P
concentrated in vacuo and the residue is stirred with about 300 ml of abs. ethanol. The suspension is cooled in ice, the precipitate is filtered off with suction, washed with ethanol and dried first at room temperature and then at 100*C in vacuo.
Yield: 13.4 g (93.8 of theory); Melting point: 328-330 0 C (with decomposition); Rf value (silica gel, methylene chloride /methanol/ 17 strength aqueous NH, 30:8:1): 0.4; Purity (HPLC): 99.9 strength, 21 -164.40 (c 0.45,H0,
C
20
H
2 lClFN 3 0 3 .HCl(442 .3) Calculated: C 51 3 H 5.0 N 9.5 Cl 16.0 Found: C 5 3 H 5.0 N 9.5 Cl 16.0 C. The following salts, for example, can also be prepared analogously: 8-chloro-1-cyclopropyl-,7-( [S,S]-2,8-diazabicyclo- 00000* [4.3.0 ]non-8-yl) -6-fluoro-1 ,4-dihydro-4-oxo-3- 0 quinoline carboxylic acid methanesulphonate o Q 20 8-chloro-l-cyclopropyl-7-([S,S]-2,8-diazabicyclo- [4.3.0 ]non-8-yl) -6-fluc 4-dihydro-4-oxo-3quinoline carboxylic acid toluenesulphonate 8-chloro-l-cyclopropyl-7-([S,S]-2,8-diazabicyclo- [4.3 .0]non-8-yl)-6-fluoro'-1,4-dihydro-4-oxo-3- Le A 28 100 quinoline carboxylic acid sulphate 8-chloro-l-cyclopropyl-7-( [S,S]-2,8-diazabicyclo- 0]non-8-yl)-6-fluoro-l,4-dihydro-4-oxo-3quinoline carboxylic acid acetate 8-chloro-l-cyclopropyl-7-( [S,SJ-2,8-diazabicyclo- 0]non-8-yl)-6-fluoro-l,4-dihydro-4-oxo-3quinoline carboxylic acid lactate 8-chloro-l-cyclopropyl-7-( [S,S]-2,8-diazabicyclo- [4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3quinoline carboxylic acid citrate o 8-chloro-l-cyclopropyl-7-( [S,S]-2,8-diazabicyclo- O C 0]non-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3quinoline carboxylic acid embonate Example 3 F COOH 04N N Analogously to Example 1, the following are obtained with l-cyclopropyl-6,7-difluoro-l,4-dihydro-4-oxo-3quinolinecarboxylic acid: Le A 28 100 -7 76 A. l1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.]non- 8-yl)-6-fluoro-1,4-dihydro-4-oxo..3-quinoline- Ifcarboxylic acid hdohoie Melting point: 20-5C (with decomposition).
I2 ICI 9.0(c 04,H0 0 9 0 26 F aO 0. c=0.8 2 H N N H F A. 6 g (20 mnol) of l-cyclopropyl-5,6,7,8-tetrafluoro- 1 ,4-dihydro-4-oxo-3-quinolinecarboxylic acid are heated under reflux for 1 hour with 2.7 g (21.4 inmol) of (+)-[S,S]-2,8-diazabicyclofj4.3.0]nonane in 15 40 ml of acetonitrile/20 iml of N-methylpyrrolidone in the presence of 2.2 g (20 mmol) of 1,4diazabicyclo[2 .2.2 ]octane. The suspension obtained is cooled, and the precipitate is filtered off with suction, washed with ac-etonitrile and dried at 100 0 C/12 mbar.
Le A28 100 77- Yield: 6.7 g (82.3 of theory) of 1-cyclopropyl-7- ([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-5,6,8-trifluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid, Melting point: 257-259 0 C (with decomposition); after recrystallisation from glycol monomethyl ether: Melting point: 260-265 0 C (with decomposition).
B. 1.5 g (3.7 nunol) of the product from Step A are introduced into 6 ml of 1 N hydrochloric acid. After a short time, the hydrochloride deposits, and is filtered off with suction, washed twice with 5 ml of ethanol each time and dried at 100*C/12 mbar.
Yield: 1.4 g (85.7 of theory) of l-cyclopropyl-7- ([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-5,6,8trifluoro-l,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride, Melting point: 310*C (with decomposition), .26 rD -2 27 20 (c 0 0.5, H 2 0).
Example
NH
2 O0 F COGH H N HF x HCI N6H 5.2 g (13 mmol) of the product from Example 4A are treated with 15 ml of liquid ammonia in 80 ml of pyridine P in an autoclave and heated at 130 0 C for 12 hours. The
Y
Le A28 100-78mixture is then cooled, the autoclave is let down, the mixture is concentrated and the residue is treated with acetonitrile in an ultrasonic bath. The undissolved precipitate is filtered off with suction, the residue is dissolved in about 150 ml of water in the presence of heat, the solution is filtered and the hydrochloride is precipitated using 10 ml of half-concentrated hydrochloric acid, filtered off with suction and dried at 100"C in a recirculating air drying oven. The product obtained is suspended in 100 ml of glycol monomethyl ether at 110-115"C and brought into solution by addition of 38 ml of half-concentrated hydrochloric acid. The solution is filtered hot through a glass frit, cooled and the cooled yellow crystallisate is filtered off with 15 suction, washed with ethanol and dried at 120"C/12 mbar.
Yield: 2.5 g (44 of theory) of 7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6,8-difluoro- S! 1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride, Melting point: 335"C (with decomposition; dark colouring already below 335"C), [a] 8 -280.8" (c 0.53, H 2 0).
SExample 6 0 F
COOH
H N N N HN x HCI
C
Le A 28 100 79 ii L .i, 1.4 g (5 mmol) of 7-chloro-1-cyclopropyl-6-fluoro-1,4dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid are stirred at room temperature for 1 hour with 1.3 g (10.3 mmol) of (+)-[S,S]-2,8-diazabicyclo[4.3.0]nonane with exclusion of water in 15 ml of acetonitrile. After standing overnight, the precipitate is filtered off with suction, washed with acetonitrile and chromatographed on silica gel for purification (eluent: methylene chloride/methanol/17 strength aqueous ammonia 30:8:1; R, value: The l-cyclopropyl-7-([S,S]-diazabicyclo[4.3.0]non- 8-yl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3carboxylic acid obtained is dissolved in 15 ml of halfconcentrated hydrochloric acid, the solution is evaporated and the residue is stirred with ethanol. The precipitate is filtered off with suction, washed with ethanol and dried at 120 0 C/12 mbar.
Yield: 960 mg (47 of theory) of l-cyclopropyl-7-([S,S]- 2 ,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-4oxo-l,8-naphthyridine-3-carboxylic acid hydrochloride Melting point: 345-346"C (with decomposition), [CI:D +5.4O (c 0.5, H 2 0).
Example 7 0 F
COOH
N A H N F Le A 28 100 Analogously to Example 1, the following are obtained using- (-)-[R,R]-2,8-diazabicyclo[4.3.0]nonane: A. 1-Cyclopropyl-7-([R,R]-2,8-diazabicyclo[4.3.0]non- 8-yl) -6 ,8-difluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid Melting point: 247-249 0 C (with decomposition).
B. l-Cyclopropyl-7-( [R,R]-2,8-diazabicyclo[4.3.0]non- 4443 8-yl) 8-difluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride, Melting point: 322-326*C (with decomposition), Purity (HPLC): 99.4 strength, ee: 98.6 [a]1D +2500 (c 0.5, H 2 0).
Example 8 0 F COOH N N4 H N N1 Analogously to Example 2, the following are obtained using (-)-[R,R]-2,8-diazabicyclo[4.3.0]nonane: A. 8-Chloro-1-cyclopropyl-7-( [R,R]-2,8-diazabicyclo- [4.3.0 Jnon-8-yl) -6-fluoro-l, 4-dihydro-4-oxoquinolinecarboxylic acid, Le A 28 100 -81- Melting point: 192-195 0 C (with decomposition).
B. 8-Chloro-l-cyclopropyl-7-( [R,R]-2,8-diazabicyclo- 3.0]non-8-yl)-6-fluoro-1,4-dihydro-4-oxoquinolinecarboxylic acid hydrochloride, Melting point: 323-324 0 C (with decomposition).
Purity (HPLC): 99.9 strength, [a3D~ +164.50 (c =0.53, H 2 0).
C
20
H
21 ClFN 3 0 3 .HC1 (442 .3) Calculated: C 54.3 H 5.0 N 9.5 Cl 16.0 ~2:10 Found: C 54.2 H 5.0 N 9.5 Cl 16.1 Example 9 0 0 F CooHiJ H N N
NH"
Analogously to Example 1, the following are obtained from 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo- 3 quinolinecarboxylic acid and (-)-[R,R]-2,8-diazabicyclo- [4.3.0]nonane: A. l-Cyclopropyl-7-( [R,R]-2,8-diazabicyclo[4.3.0]nofl- 8-yl)-6-fluoro-1, 4-dihydro-4-oxo-3-quinolilecarboxylic acid, Melting point: 254-258 0 C (with decompositiaQ Le A28 100 -82- B. l-Cyclopropyl-7-( [R,R]-2,8-diazabicyclo[4.3.0]non- 8-yl)-6-fluoro-l, 4-dihydro-4-oxo-3-quinolinecarboxylic acid, Melting point: decomposition above 320*C, 24 :UI +92.5' (c 0.53, H 2 0).
Example 0 F COOH N N H ,N C iS F A. l-Cyclopropyl-6,8-difluoro-l,4-dihydro-7-(cis-2-oxa- 0 05, 8-diazabicyclo 4. 3. 0] non- 8-yl) -4-oxo-3-quinolinecarboxylic acid: V, 10 1.43 g (5 mmol) of l-cyclopropyl-6,7,8-trifluoro- 041, 4-dihydro--4-oxo-3-quinolinecarboxylic acid are heated under ref lux for 1 hour with 0.74 g (5.4 minol,) of 93 strength cis-2-oxa-5,8-diazabicyclo[4.3.0]nonane in the presence of 0.67 g (6 mmol) of 1,4-diazabicyclo[2.2.2]octane in a mixture of 15 ml of acetonitrile/75 ml of diiethylformamide.
The suspension is concentrated, the residue is stirred with water, and the precipitate is filtered off with suction and dried in vacuo at Yield: 1.67 g (85.4 of theory), Melting point: 210-212 0 C (with decomposition).
Le A28 100-83- B. 1-Cyclopropyl-6, 8-dif luoro-l, 4-dihydro-7- (cis-2-oxa- 5,8-diazabicyclo 0] non-8-yl) -4-oxo-3-quinolinecarboxylic acid hydrochloride: 1. 6 g (4 mmol) of the product from Step A are dissolved in 120 ml of half -concentrated hydrochloric acid at 60'C, the solution is concentrated, the residue is stirred with ethanol and the precipitate is filtered off with suction and dried at in vacuo.
Yield: 1.57 g, Melting point: 300-303'~C (with decomposition), Purity (HPLC) 97 strength.
C. Analogously to Example 10A, 1-cyclopropyl-6,8difluoro-l,4-dihydro-7-(lR,6S-2-oxa-5,8diazabicyclo[4.3.0]non-8-yl)-4-oxo-3-quinoline- V4. carboxylic acid of melting point 204-2060C (with decomposition) is obtained using lR,6S-2-oxa-5,8diazabicyclo[4.3. Olnonane.
D. Analogously to Example lOB, 1-cyclopropyl-6,8difluoro-l, 4-dihydro-7-( iR, 6S-2-oxa-5, 8os diazabicyclo non-8-yl) -4-oxo-3-quinolinecarboxylic acid hydrochloride of melting point 324- 325 0 C (with decomposition) is obtained using the betaine from Example [a]1D -241* (c 0.59, 1120).
Le A 28 100 84 E. Analogously to Example 10A, l-cyclopropyl-6,8difluoro-1,4-dihydro-7-(lS,6R-2-oxa-5,8diazabicyclo [4.3.01 non-8-yl) -4-oxo-3-quinolinecarboxylic acid of melting point 204-206 0 C (with decomposition) is obtained using lS,6R-2-oxa-5,8diazabicyclo [4 .3.0 Inonane.
[aID +2480 (c 0.57, DMF).
F. Analagously to Example 10B, l-cyclopropyl-6,8difluoro-1,4-dihydro-7-(lS,6R-2-oxa-5,8diazabicyclo [4 non-8-yl) -4-oxo-3-quinolinecarboxylic acid hydrochloride of melting point 323 0
C
(with decomposition) is obtained using betaine from Example [a]1D +2380 (c 0.5, H 2 0).
00 0 4 Example 11 COO H 0 Analogously to Example 10, the following are obtained using 8-chloro-l-cyclopropyl-6,7-difluoro-1,4-dihydro-4oxo-3-quinolinecarboxylic acid: Le A 28 100 85 Ji- A. 8 -Chloro-l-cyclopropyl-6-fluoro-1,4-dihydro.7-(cis- 2-oxa-5,8-diabicycl43.lon4...8...yl....4 oxo3...
quinolinecarboxylic acid, Melting point: 180-185 0 C (with decomposition).
B. 8-Chloro-l-cyclopropyl-6-fluoro-,4dihydro-.>(cis- 8-diazabicyclo[4. 3.]non-8-y..4o3 guinolinecarboxylic acid hydrochloride, Melting point: 227-232'C (with decomposition).
C. 8-Chloro-l-cyclopropyl-6-fluoro-l .4-.dihydro-7- 3-quinolinecarboxylic acid, 0 0 Melting point: 186-188 0 C (with decomposition).
~~0001 -269 0 (c 0.5, DMF).
D. 8-Chloro-l-cyclopropyl-6-fluoro-1 ,4-dihydro-7- Melting point: 278-280*C (with decomposition).
C,0 Ic]~ D 2080 (c 0.51 H 2 0)' E. 8-Chloro-l-cyclopropyl-6-fluoro-l, 4-dihydro-7- (lS,6R-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-4-oxo- Melting point: 188-190 0 C (with decomposition).
[a]D :+2700 (c DMF).
Le A 28 100 -86- F. 8-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7- (iS, 6 R- 2-oxa-5, 8-diazabicyclo 4. 3. 0] non- 8-yl) -4-oxo- 3-quinolinecarboxylic acid hydrochloride, Melting point: 292-294 0 C (with decomposition).
27 1[a]D +1930 (c 0.5, H 2 0).
Example 12 0 F COOH 0' N cis 0 0 o o 0Analogously to Example 10A, the following are obtained using l-cyclopropyl-6,7-dif luoro-l,4-dihydro-4-oxo-3quinolinecarboxylic acid: 0 A. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(cis-2-oxa-5,8- 0:.:diazabicyclo 4.3.o0]non-8-yl) -4-oxo-3-quinolinecarboxylic acid, Melting point: 246-249 0 C (with decomposition) (from *0 glycol monomethyl ether).
B. l-Cyclopropyl-6 -f luoro-l, 4-dihydro-7I- (1R, 6S-2-oxa- 5,8-diazabicyclo[4.3.0]non-8-yl)-4-oxo-3-quinolinecarboxylic acid, Melting point: 243-245 0 C (with decomposition) Le A28 100 -87- C. 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(lR,6S-2-oxa- 8-diazabicyclo [4 0] non-8-yl) -4-oxo-3-quinolinecarboxylic acid hydrochloride, Melting point: 300 0 C (decomposition) [a]ID -990 (c 0.5, H 2 0).
it Example 13 F 0 F COOH
N
0 o 00Analogously to Example 10Aur, tefollowing aeobtained using 1-cyclopropyl-5,6, 7,8-tetrafluoro--l,4-dihydro-4oxo-3-quinolinecarboxylic acid: A. 1-Cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-2- ,8-diazabicyclo non-8-yl) -4-oxo-3quinolinecarboxylic acid, Melting point: 210-216 0 C (with decomposition).
B. l-Cyclopropyl-5,6,8-trifluoro-1,4-dihyvdro-7-(lR,6S- :2 15 2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-4-oxo-3quinolinecarboxylic acid, Melting point: 234-237 0 C (with decomposition).
[Cx]1D -2870 (c DMF).
Le A28 100 88na -IGIWNN I "E C. l-Cyclopropyl-5,6,8-trif luoro-1,4-dihydro-7- (1S, 6R- 8-diazabicyclo[4. 3.0O]non-8-yl)-4-oxoquinolinecarboxylic acid, Melting point: 236-237 0 C (with decomposition).
+2820 (c 0.5, DMF).
Example 14
NH
2 O0 F COOH
N*
PF
N c, boo0)0 0 C0 00 A. 4.1 g (10 mnol) of the product from Example 13A are treated with 5 ml of liquid ammonia in 40 ml of 0 0 pyridine and heated at 130 0 C for 10 hours in an 00010 autoclave. After cooling, the precipitate is filtered off with suction, washed with water and 0 0 dried at 100 0 C in a recirculating air drying oven.
The crude product (2 g) is purified by recrystalli- 0 5sation from glycol monomethyl ether: yellow crystallisate.
4 ~0Yield: 1.3 g (31 of theory) of cyclopropyl-6 ,8-difluoro-1, 4-dihydro-7- (cis-2-oxa- 8-diazabicyclo [4 non-8-yl) -4-oxo-3-quinolinecarboxylic acid, Melting point: 233-240 0 C (with decomposition).
Le A 28 100 -89- I B. 5-Amino-l-cyclopropyl-6,8-difluoro-1,4-dihydro-7- (1R,6S-2-oxa-5,8-diazabicyclo[4.3.lnon -8.yl) -4-oxo- 3-quinolinecarboxylic acid is obtained analogously using the product from Example 13C, Melting point: 212-214 0 C (with decomposition), 2600 (c 0.5, DMF).
C. 5-Amino-l-cyclopropy-6,8-difluoro-1,4-dihydro.> (lS,6 R-2 -oxa-5,8-diazabicy lnr4.3. 0]non-8-yl) -4-oxo- 3-quinolinecarboxylic acid is obtained analogously using the product from Example 13C, Melting point: 213-215 0 C (with decomposition), [c]26: +2610 (c 0.5, DMF).
Mass spectrum: 406 (M,95 346, 249, 98, 41, 28 (100 15 Example o o* .44 F[;Ik COO- C"-i 2 CH- CH 2
CH
3 NJ
CH
3 HIN iS F A xCCO
O
H
A. 2-tert-Butoxcarbonyl-2, 8-diazabicyclo[4 0 ]non- 8-yl)-l-cyclopropyl.-6,8-difluoro 1,4-dihydro-4-oxo- 3-quinolinecarboxylic acid Le A 28 100 .L L
K
7.8 g (20 mmol) of l-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6,8-difluoro-l,4-dihydro-4oxo-3-quinolinecarboxylic acid are dissolved in a mixture of 60 ml of dioxane/water and 20 ml of 1 N sodium hydroxide solutic and the mixture is treated with ice-cooling and stirring with 5.24 g (24 mmol) of di-tert-butyl pyro-carbonate. The mixture is stirred at room temperature for 1 hour and allowed to stand overnight. The deposited precipitate is filtered off with suction, washed with 250 ml of water and dried overnight at 50"C in a recirculating air drying oven.
Yield: 9.34 g (95.5 of theory), 00 Melting point: 216-219"C (with decomposition).
0 0 9 0 I B. 2S-Methyl-1-butyl 7-(2-tert-butoxycarbonyl-2,8diazabicyclo[4.3.0]non-8-yl)-l-cyclopropyl-6,8difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate 2.15 g (4.4 mmol) of the product from Step A are suspended in 60 ml of tetrahydrofuran/water at room temperature and 1.65 g (5 mmol) of cesium carbonate are added. The mixture is allowed to react at about 40"C in an ultrasonic bath for 20 minutes, iabout 40 ml of the solvent are distilled off at 40°C/12 mbar) and the solution which remains is lyophilised, the slightly soluble crude caesium salt being obtained. 3.3 g of this crude salt are dissolved in 40 ml of dimethylformamide and treated with 1.4 g of S(+)-l-bromo-2-methyl-butane and Le A 28 100 91 ii reacted overnight in the ultrasonic bath at 40-50"C.
The suspension obtained is concentrated, and the residue is treated with water and extracted with methylene chloride. After drying with sodium sulphate, the solution is concentrated and the residue is purified by chromatography (silica gel, eluent: methylene chloride/methanol 95:5).
Yield: 950 mg (38 of theory), Melting point: 72-83°C (with decomposition).
10 C. 2S-Methyl-l-butyl l-cyclopropyl-7-(2,8-diazabicyclo- [4.3.0]non-8-yl)-6,8-difluoro-1,4-dihydro-4-oxo-3quinolinecarboxylate trifluoroacetate o 4 4 S* 570 mg (1 mmol) of the product of Step B are dissolved in 3 ml of trifluoroacetic acid at room temperature and the solution is concentrated at 0 C/12 mthr. The viscous oil obtained is stirred with 5 ml of ether, a solid product being obtained.
This is filtered off with suction, washed with ether and dried at 80 0 C in a high vacuum.
S 20 Yield: 450 mg (78 of theory), Melting point: 214-216 0 C (with decomposition), l25.
'or (c 0.5, DMF).
-a Example 16 0 F COOH
N
CH- NH- CO
F
CH
3 Le A 28 100 92 V W 390 mg (1 mmol) of 1-cyclopropyl-7-(2,8-diazabicyclo- [4.3.0]non-8-yl)-6,8-difluoro-1,4-dihydro-4-oxo-3quinolinecarboxylate are dissolved in a solution of 40 mg of sodium hydroxide in 3 ml of water at room temperature in an ultrasonic bath and the solution is treated with ice-cooling with a solution of 160 mg (1.1 mmol) of R- (+)-a-methyl-benzyl isocyanate. The deposited precipitate is filtered off with suction, washed with dioxane and dried at 100"C in a high vacuum.
Yield: 530 mg (99 of theory) of l-cyclopropyl-6,8difluoro-1,4-dihydro-4-oxo-7- 1R-phenyl-ethyl-aminocarbonyl]-2,8-diazabicyclo[4.3.0]non-8-yl)-3-quinolinecarboxylate, Melting point: 208-210 0 C (with decomposition), 15 -23.2 (c 0.5, DMF).
*The reaction product can be separated into the diastereomers by chromatography and the carbamoyl radical removed again by acidic hydrolysis, the compounds of Examples 1 and 7 being obtained.
Example 17
O
F C0 2
C
2
H
H N N H,
F
H8 H Le A 28 100 93 i L _.r 1.52 g (5 mmol) of ethyl l-cyclopropyl-6,7,8-trifluoro- 1, 4 -dihydro-4-oxo- 3-quinol inecarboxyl ate are reacted with 550 mg (5 mmol) of 1,4-diazabicyclo[2.2.2]octane and 760 mg (6 mmol) of (+)-[S,S]-2,8-diazabicyclo-[4.3.Ojnonane in 30 ml of acetonitrile for 2 hours at 50 0 C and for 2 hours at 60 0 C. After cooling, the suspension obtained is filtered off with suction, and the precipitate is washed with water and dried at 90*C in vacuo.
Yield: 0.99 g (47.5 of theory) of ethyl 1-cyclopropyl- [S,S]-2,8-'diazabicyclo[4.3.0]non-8-yl)-6,8-difluoro- 1, 4-dihydro-4-oxo-3-quinolinecarboxylate, Melting point: 194-195 0 C (from acetonitrile), 23 1C1 188.90 (c 0.51, CHCl 3 Example 18
COGH
H
H,
N'
H 6 ),CH 3 1.4 g (5 mmol) of 9,10-difluoro-.2,3-dihydro-3-methyl-7oxo-7H-pyrido[1,2,3-de][1,4]-benzoxacine-6-carboxylic acid are reacted with 0.85 g (7.7 inmol) of 1,4diazabicyclo[2.2.2 ]octane and 0.7 g (5.6 mmol) of [S,S]-2,8-diazabicyclo[4.3.0]nonane in 15 ml of acetonitrile/7.5 ml of dimethyfornaiide analogously to Example 1.
Yield: 1.24 g (64 of theory) of diazabicyclo non-8-yl) -9-fluoro-2, 3-dihydro-3-
OW
Le A 28 100 94
L
methyl- 7 -oxo-7Hpyrido[1,2,3de][1,4]benzoxacine6.
carboxylic acid, Melting point: 265-268 0 C (with decomposition), [ae]D: -232,2* (c 0.58, CHCl 3 3 S-lO-([S,S]-2,8-Diazabicyc[4..]no~n.-.yl).. 9 fluoro- 2.,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3de][l,4]benzoxacine-6-carboxylic acid is also obtained analogously.
Example 19 0 F COOH 0.H6
NN
00 H
OCH
3 S* 10 l-Cyclopropyl-6, 7 -difluoro-1,4-dihydro-8-methoxy-4-oxo- 3-quinolinecarboxylic acid is reacted analogously to Example 1 and the reaction product is purified by 00chromatography (silica gel, eluent: methylene chloride/methanol/l7 strength aqueous ammonia 30:8:1).
l-Cyclopropyl-7-( [S,S]-2,8-diazabicyclo[4.3.0]non-8-yl).
6-fluoro-1,4-dihydro-8methoxy4oxo-3 00 0 quinolinecarboxylic acid of melting point 203-208 0 C (with 0 decomposition) is obtained.
[Cr]1D 1930 (c CHCl 3 Le A28 100
I
Example F COOR H N N* H 5 F I N H
C
2
H
The reaction is carried out analogously to Example 1A uasing l-ethyl-6,7,8-trif luoro-l, 4-dihydro-4-oxo-3quinolinecarboxylic acid and l-ethyl-7-( diazabicyclo[4.3. 0]-non-8-yl) -6,8-dif luoro-l, 4-dihydro- 4-oxo-3-quinolinecarboxylic acid of melting point 236- 239 0 C (with decomposition) is obtained (recrystallised from glycol monomethyl ether); [C,3D -186.30 (c 0.3, CHCl 3 p a a a a 10 Example 21
H
H,,
COGH
F
X HCL StOaa I A. Ethyl 7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-l- (2 ,4-difluorophenyl) -6-f luoro-l, 4-dihydro-4-oxo-l, 8naphthyridine- 3-c arboxyl ate 1.9 g (5 mmol) of ethyl 7-chloro-l-(2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-1,8naphthyridine-3-carboxylate are stirred at 100C for Le A,28 100 -9 96 3 hours with 680 mg (5.4 mmol) of diazabicyclo[4.3.0]nonane in the presence of 560 mg mmol) of 1,4-diazabicyclo[2.2.2]octane in 20 ml of acetonitrile. The suspension is filtered off with suction, washed with water and dried. 0.35 g of product is obtained. By concentrating the mother liquors, stirring the residue with water, isolating the undissolved product and purifing by chromatography (silica gel, eluent: dichloromethane/methanol/17 strength aqueous ammonia), a further 0.7 g of product is isolated.
Total yield: 1.05 g (44 of theory), Melting point: 184-185"C (with decomposition) +6.8 (c 0.46, CHC1 3 15 B. 7-([S,S]-2,8-Diazabicyclo[4.3.0]non-8-yl)-l-(2,4difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,Snaphthyridine-3-carboxylic acid hydrochloride 0.8 g (1.7 mmol) of the product from Step A are heated under reflux for 4 hours in a mixture of 20 10 ml of acetic acid and 8 ml of half-diluted hydrochloric acid. The mixture is concentrated, the residue is stirred with a little water, and the precipitate is filtered off with suction, washed with ice-cold ethanol and dried.
25 Yield: 0.67 g (83 of theory), Melting point: 324-326°C (with decomposition), [C]Dt +10.8° (c 0.37, DMF).
Le A 28 100 97o Example 22
CH
3 O0 F:I: COOH H N N H N
H
040S 0000 o 0t 00.4 00 I~ 1 0 00 0000 0.56 g (2 nunol) of 1-cyclopropyl-6,7-difluoro-1,4dihydro-5-methyl-4-oxo-3-quinolinecarboxylate are heated at 120 0 C for 2 hours with 0.38 g (3 mmol) of diazabicyclo[4.3.0]nonane and 0.45 g (4 mmol) of 1,4-diazabicyclo[2.2.2]octane in 3.5 ml of dimethyl sulphoxide. After cooling, the solvent is removed in a high vacuum. The residue is taken up with acetonitrile.
The solid is separated off, washed with acetonitrile and dried at 60 to 800C.
Yield: 0.5 g (65 of theory) of 1-cyclopropyl-7-([S,S]- 2, 8-diazabicyclo [4.3.0 ]non-8-yl) -6-fluoro-1 ,4dihydro-5-methyl-4 -oxo-3-guinolinecarboxylate Melting point: 217-2190C (with decomposition), [cQ]n: -1190 (c DI4F) Example 23
COOH
Le A 28 100 98
L"
9*99 9 t9 A. 837 mg (3 nmol) of l-cyclopropyl-6,7-difluoro-1,4dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid are heated under reflux for 2 hours with 1-1 g mmol) of 1,4-di azabicyclo[2.2.2]octanle and 665 mg (3.3 mmol) of 1R, 6S-2-oxa-5,8-diazaibicyclo[4.3.0]nonane-dihydlochloride in a mixture of ml of acetonitrile and 5 ml of dimethylformmide The mixture is evaporated, the residue is stirred with 30 m- of water, and the precipitate is filtered off with suction and dried at 80 0 C in vacuo.
Yield: 400 mg (34 of theory of the carboxylic acid of the formula.
Melting point; 213-214 0 C (with decomposition).
B. 0.4 g of the betaine from Step A is dissolved in 5 ml of half-concentrated hydrochioric acid at room temperature, the solution is concentrated and the residue is stirred with about 3 ml of ethanol- The precipitate is filtered off with suction and dried at 800/12 mbr.
Yield; 290 mg (66 of theory) of the hydrochloride of the carboxylic acid of the formula.
Melting paint: 305-30s8C (with decomposition), z 3: -79' (c 0.52, 99 99 Tt:TT 96, VO/69 1, O Io NOSITI0o Sa!AVQ OROTz99 9 T94g f I ~II~ I-L Example 24 Br 0 F CO H N N HN H 362 mg (1 nunol) of 5-bromo-l-cyclopropyl-6,7,8-trifluoro- 1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid are heated under reflux for 1.5 hours with 220 mg (2 inmol) of 1,4diazabicyclo[2.2.2 ]octane and 220 mg (1.1 mmol) of 1S,6R- 8-diazabicyclo[4 0]nonane dihydrochioride in a mixture of 3 ml of acetonitrile and 1.5 ml of dimethylformainide. The suspension is cooled, and the precipitate is filtered off with suction, stircred with 30 ml of water 10 and dried at 90'C in a high vacuum.
Yield: 320 mg (68 of theory) of G,8-difluoro-1 ,4-dihydro-7-(lS,6R-2-oxa-5,8-diazabicyclo[4 0]non-8-yl)-4-oxo-3-quinolinecarboxylic acid, Melting point: 263-264 0 C (with decomposition), [CZ 3 +2510 (c CH 2 Cl 2 Example 0 COGH \H NN
CH_;
3 141F
IN
iiH Le A 28 100-10 100 Analogously to Example 1, the following are obtained using [S,S]-2-methyl-2,8-diazobicycio[4.3.0]nonane: A: l-Cyclopropyl.-6,8-difluoro-l,4-dihydro-7-( methyl-2 ,8-diazobicyclo non-8-yl) -4-oxo-3quinolinecarboxylic acid, melting point: 230-233 0 C (with decomposition) (recrystallised from glycol monomethyl ether); B. l-Cyclopropyl-6,8-difluoro-1,4-dihydro-7-( methyl-2, 8-diazobicyclo[4 0]non-8-yl) -4-oxo-3quinolinecarboxylic acid hydrochloride, melting point: 258-260 0 C (with decomposition), 0 08 Example 26 08 8 0 F COOH 8088 H N N o9 IOH 3 F Analogously to Example 1, the following are obtained using [R,R]-2-methyl-2,8-diazabicyclo[4.3.0]nonane: A: 1-Cycopropyl-6,8-difluor-o-1,4-dihydro-7-( methyJ-2,8-diazabicyclo[4.3.0]non-8-yl)-4-oxo-3quinolinecarboxylic acid, S8melting point: 228-230 0 C (with decomposition) (recrystallised from glycol monomethyl ether): B: 1-Cyclopropyl-6,8-difluoro-,4-dihydro-7-( methyl-2,8-diazabicyclo[4.3.0]non-8-yl)-4-oxo-3- Le A 28 100-10 101 guinolinecarboxylic acid hydrochloride, melting point: 258-260*C (with decomposition), [CX]D +213.80 H 2 0).
Example 27
COOH
CH
3 -CO-CH 2 CH,
H
F Ak 0 0C 0 0 4 1.95 g (5 inmol) of the product from Example 1A are heated under reflux for 4 hours with 2.1 g (30 inmol) of methyl vinyl ketone in 50 ml of ethanol. The mixture is concentrated, the residue is stirred with water, and the precipitate is filtered off with suction, washed with ethanol and dried at 100 0 C/12 mbar.
Yield: 2.1 g (91.5 of theory) of 1-cyclopropyl-6,8difluoro-1,4-dihydro-oxo-7-( [S,S]-2-[3-oxo-l-butyl]-2,8diazabicyclo[4 0]non-8-yl)-3-quinolinecarboxylic acid, Melting point: 181-183 0 C (with decomposition) (recrystallised from glycol monomethyl ether, 24=CHC 2 [D :-120.70 (c =0.57, HC2 j44 Le A 28 100-10 102 e_ Example 28
COOH
CH
3
-CO-CH
2
SA
o 0 0 00a 0 0 l 0
I.I
Il 1.95 g (5 mmol) of the product from Example 1A are heated at 50-80°C for 3 hours with 1.0 g (10.8 mmol) of chloroacetone and 1.3 g (13 mmol) of triethylamine in 30 ml of dimethylformamide. The solution is concentrated, the residue is stirred with water (pH and the undissolved precipitate is filtered off with suction, washed with water and dried at 100°C in a recirculating air drying oven (crude yield: 1.3 g) and recrystallised 10 from glycol monomethyl ether: Yield: 1.12 g (50 of theory) of l-cyclopropyl-6,8difluoro-1,4-dihydro-4-oxo-7-( [S,S]-2-[2-oxopropyl]-2,8diazabicyclo[4.3.0]]non-8-yl)-3-quinolinecarboxylic acid, Melting point: 181-184 0 C (with decomposition), [aC]3:-72° (c 0.55, CHCU1).
fi 4 r *r 04 C *444 Example 29
F,
H N
CH
3
-CO-CH
2
CH
2
N
Le A 28 100 103 Le A 28 100 103
.COOH
Cl A. The product from Example 2A is reacted analogously to Example 27 and 8-chloro-1-cyclopropyl-6-fluoro- 1,4-dihydro-4-oxo-7-'([S,S]-2-[3-oxo-l-butyl]-2,8diazabicyclo [4 0]non-8-yl) -3-quinolinecarboxylic acid of melting point 107-109*C is obtained.
(a]D -530 (c 0.67, CHCl 3 Purity: 99.2 strength (HPLC).
B. Rac. 8-chloro-l-cyclopropyl-6-fluoro-1,4.-di*hydro-4oxo-7-cis-2- [3-oxo-l-buty 2,8-diazabicyclo[4.3.0]non-8-yl)-3-quinolinecarboxylic acid of melting point 124-125 0 C is obtained analogously using 8chloro-1-cyclopropyl-7-(cis-2,8.-diazabicyclo[4.3.0]- :0::non-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin', carboxylic acid.
Example 0 *F COGH N~Nf aCH 3
-CO-CH
2
F
L .1.56 g (4 mmol) of the product from Example 10A are treated with 0.82 g (8.8 mol) oL chloroacetone and 1.05 q (10.4 n'ixol) of triethylamine in 30 ml of dixnethylforinamide and the mixture is heated at 50-80'C for 3 hours. The yellow solution obtained is concentrated at Le A28 100 -104- 0 C/15 mbar, and the oily residue is stirred with water until it scu3idifies. The solid product is filtered off with suction, washed with water and recrystallised from glycol monomethyl ether.
Yield: 830 ing (47 of theo,i.y) of l-cyclopropyl-6,8difluoro-l,4-dihydro-4-oxo-7-(cis-5-[2-oxopropyl]-2-oxa- 5,8-diazabicyclo[4.3.O]non-8-yl)-3-quinolinecarboxylic acid, Melting point: 192-193*C (with decomposition).
Exam~ple 31 0 F cooH NN N
CH
3
-CO-CH
2 CH4 2 F~ 1.56 g (4 mmol) of the product from Example 10A are heated under ref lux for 3 houri, with 1.8 g (25.6 mmol) of C methyl vinyl ketone in 50 ml cf ethanol. The suspension 1 is concentrated at 70 0 C/12 mbar, and the residue is stirred with water and recrystallised from glycol 4 monomethyl ether.
Yield: 1.33 g (72 of theory) of 1-cyclopropyl-6,8- I difluoro-1,4-dihydro-4-oxo-7-(cis-5-[3-oxo-l-butyl]-2- Le A 28 100 105
-I'
f ,8-diazabicyclo [4.3.0 ]non-8-y.) -3quinolinecarboxylic acid, melting point: 188-1890C (with decomposition).
Example 32
COOH
C
2
H
5 0 2
C-CH
2
-CH
2
-H
4
H/
00 04 0 6 1.95 g (4.8 mmol) of the product from Example 2A are heated under reflux for 2 hours with 3 g (30 mmol) of ethyl acrylate in 30 ml of glycol monomethyl ether. The mixture is evaporated, the residue is stirred with water, and the precipitate is filtered off with suction, dried (Crude yield: 1.9 g) and recrvq-tallised from glycol monomethyl ether.
Yield: 1.45 g ('50 of theory) of 8-chloro-l-cyclopropyl- 7-([S,S]-2-[2-ethoxy-carbonyl-ethyl]-2,8diazabicyclo 4. 3. 0] non- 8-yl) 6-f luoro-l1, 4-dihydro-4 -oxo- 3-quinolinecarboxylic acid, Melting point: 117-118'C (with decomposition), 28o [a1D -103.50 (c 0.49, DMF), Purity: 99.6 strength (HPLC).
Le A 28 100 106
L
Example 33 0 F COGH H N C 1.95 g (4.8 mmol) of the product from Example 2A are heated under reflux for 5 hours with 0.8 g (15 mmol) of acrylonitrile in 30 ml of ethanol. The mixture is 5 evaporated, and the residue is stirred with water, dried o (crude yield: 1.9 g) and recrystallised from glycol o monomethyl ether.
Yield: 1.6 g (73 of theory of 8-chloro-7-([S,S]-2-[2cyanoethyl] 8-diazabicyclo 0] non-8-yl cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid, A AA: Melting point: 153-155*C (with decomposition), Purity: 96 strength HPLC), A 15 Mass spectrum: m/e 458 250, 149 (100 %,C 9 Hl 3
N
2 110, 49.
Le A28 100 -107- Example 34
COOH
CH
3 00C
CH=CU
F
H A
CH
3 00C 00* 0 o I 000*90 0 9 a 1.95 g (5 mmol) of the product from Example 1A are heated under ref lux for 2 hours with 1.2 g (8 mmol) of dixnethyl acetylenedicarboxylate in 60 ml of ethanol. The 5 suspension is concentrated, the residue is stirred with water, and the precipitate is filtered off with suction and dried. The crude product (2.3 g) is recrystallised from glycol monomethyl ether/dimethylformamide.
Yield: 2 g (74 of theory) of 1-cyclopropyl-7-[2-(1,2methoxycarbonyl-vinyl) -1S, 6S-2,8-diazabicyclo[4. 3. 0]non- 8-yl 8-difluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid, Melting point: 262-2640C (with decomposition); +28.80 (c =0.24, CH 2 Cl 2 .4 Example
*COOH
CH
3 00C
IH
CH=C
_N'
CH
3 00C Le A 28 100 H
A
108 The product from Example 2A is reacted with dimethyl acetylenedicarboxylate analogously to Example 34. 8- Chloro-l-cyclopropyl-7- 2-bis-methoxycarbonylvinyl)-lS,6S-2,8-diazabicyclo[4.3.0]non-8-yl]-6-fluorol,4-dihydro-4-*oxo-3-quinolinecarboxylic acid of melting pcint 210-212"C (with decomposition) is obtained in 87 yield; 24 [a]D +16.60 (0 0.5, DMF).
Example 36 0 F :QNCOOH N N
C
2 H O 2
CH:CHF
4C i S 780 mg (2 mmol) of l-cyclopropyl-7 -(cis 8-diazabicyc lo- [4.3.0]non-8-yl)-6,8-difluoro-1,4-dihydro-oxo-3-qulinolinecarboxylic acid are heated under reflux for 1 hour with 500 mg (5 mmol) of ethyl propiolate in 15 ml of ethanol.. The suspension is cooled, and the precipitate is 15 filtered off with suction, washed with 25 ml of ethanol and dried at 80 0 C in a high vacuum.
Yield: 880 mg (90 of theory) of 1-cyclopropyl-7-[2- (trans-2-ethoxycarbonylvinyl)-cis-2,8-diazabicyclo- [4.3.0]non-8-yl]-6,8-difluoro-1,4-dihydro-4-oxo-3quinolinecarboxylic acid, Le A28 100 109 F1
A~
Melting point: 244-246 0
C.
Analogously to Example 36, the following are obtained from the corresponding starting materials: COrl ro QS o 0 4 040Ir :2:r Le A 28 100 110 L i: 1. 1 C COCCCCO 0
C
COOH
C
2
H
5 0 2 C
H
C=C
EKapleStarting material Exampleexampie) 37 2A 38 22 39 3A 5 41 6 42 19 43 13C 44 IA *)not recrystallised XI y Melting point
I~
[cL] D i i
CCI
CH
CH-
CF
N
C-OCIH
3
CF
CF
H
Cl1I 3
H
NH
2
H-
H
F
it' Cl- 2
CH
T 2 C-1 2
CH
2 CL1 2
CH-
2 0 Cl-1 2 211-213 199-201 284-286 246-248 219-221 232-233 225-227*) +6,30 CHC1 3 -205' CH'CI 3 -2310 CHCI 3 -14' Cl-Id 3 -162' (c=0,25, Cl-Id 3 -23' (c=0,25, CHC1 3 ±80 Cl-IC1 3 a acz. a a Analogously to Example 10, the following are obtained from the corresponding intermediate products: F C0014I N A -N C 2
H
5 0 2 C 1-H c=C\ Example 'Starting material ____(example) 46 1IC x 1
Y
melting point
[CC]
[aXID +20I~5 LI 3
CF
CCO
CF
208-209 197-199 230-232 46' CHICI 3 Example 48
COOH
CH
3
O
2
C\
C:: Iz 00 0 8-Chloro-1-cyclopropyl-7([,S]..2,8diazabicyclo [4 .3 non-8-yl) -6-f luoro-1, 4-dihydro-4-oxo- 3-quinolinecarboxylic acid is reacted with methyl propiolate in ethanol or methanol analogously to Example 36 and 8-chloro-l-cyclopropyl-6-fluoro-1,4-dihydro..>[2- (trans 2-methoxyc arbonyl -vinyl)-[ S, S j2, 8diaz abicyc lo.
4 3 .O]non-8-yl)-4-oxo-3-quinolinecarboxylic acid of melting point 220-222*C (with decomposition) is obtained, (c 0.5, CHCl 3 Example 49 00.20 000 lot 0000 0 F COGH N D N C!
/H
HRO
2 H 0 407.5 g (1 inmol) of 8-chloro-l-cyclopropyl-6-fluoro-l,4diyr--(S R2-x-,8-iaaiyl 0nn -l Le A 28 100 113- 4-oxo-3-quinolinecarhoxylic acid (from Example 11E) are heated under reflux for 1 hour with 210 mg (2.5 mmol) of methyl propiolate in 10 ml of methanol. The mixture is concentrated and the isolated crude product (450 mg) is recrystallised from 4 ml of acetonitrile.
Yield: 8-Chloro-i-cyclopropyl-6-fluoro-,4-dihydro-7-[5- (trar-s-2-methoxycarbonyl-vinyl)-S,6R-2-oxa-5,8diazabicyclo[4.3.0]non-8-yl]-4-oxo-3-quinolinecarboxylic acid, Melting point: 153-156 0 C (witi decomposition), [a] 8 +360 (c 0.5, CHCl 3 .44* Example F 0 4 F COOH
H
CH302C N /C=C N' FL HOcis 4 Reaction with the compound of Example 13A is carried out analogously to Example 49 and l-cyclopropyl-5,6,8trifluoro-1,4-dihydro-7-[5-(trans-2-methoxycarbonylvinyl)-cis-2-oxa-5,8-diazabicyclo[4.3.0]non-8-y1]-4-oxo- 3-quinolinecarboxylic acid of melting point 169-170'C (with decomposition) is obtained (from glycol monomethyl ether).
Le A 28 100 -114 Example 51
COOR
CH
3 0 2 C H H~rN
H
Or, 0 0*00 0 0 000400 0 0 00 0 040004 0001 0000 Reaction is carried out with the compound from Example analogously tCo Example 49 and l-cyclopropyl-6,8difluoro-l,4-dihydro-7-[5-(trans-2-methoxycarbonylvinyl)-lS,6R-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl]-4oxo-3-quinolinecarboxylic acid of melting point 230-234 0
C
(with decomposition) is obtained (from glycol monome-:hyl ether); -2 7 (c 0 CHCl 3 Example 52 Br 0
COOH
CH
3 O2C
H
H
N
C\
0H
F/I
i t
V
4f
A
Reaction is carried out with the compound from Example 24 analogously to Example 49 and 5-bromo-1-cyclopropyl- 6,8-difluoro-1,4-dihydro-7-[5-(trans-2-methoxycarbonyl- Le A 28 100-15- 115
II-
vinyl)-1S,6R-2-oxa-5, diazabicyclo[4.3.0]f 8 -yl]-4oxo-3-qinollecarioxylic acid of melting point 158-160*c (with decomposition) is obtained (from isopropanol); [aB +S (C=0.27, CEC13).
Exmnple 53 0 F C0 2
C
2
H
TAI f cH302C N N /S H0 Reaction is carried out with.
17 analogously to Exaple 36 of melting point 168-169 0 C is the compound from Example The compound of the formula obtained- 4.44 *r S I r Examnple 54
I
:r
I
I
F 0 F r COOH C0 2
C
2 R1 5 /H r-N N
C
2
H-
5 0C-C= C F L N i'l H 0 44*' o 44 o 4 I a, I 116
TTOZ~
NOSITIOD SHIAO.
OROT99Z 9 T9Qg Tr:TT 96, M'69Z 818 mg (2 Inmol) of 1-cyclopropyl-5,6,8-trifluoro-1,4dihycro-7 6 S- 2-oxa-5, 8-dia zabicyc lo 0 ]non- 8-yl) 4-oxo-3-quinolinecarboxylic acid (from Example 13B) are ij treated with 680 mg (4 im~iol) of diethyl acetylenedicarboxylate in 15 ml of ethanol and the mixture is treated in an ultrasonic bath at 30*C for 1 hour. The suspension is filtered off with suction, and the precipitate is washed with ethanol and dried at 70 0 C in a high vacuum.
Yield: 890 mg (77 of theory) of (1,2-bis-ethoxycarbonyl-vinyl)-lR,6S-2-oxa-5,8diazabicyclo[4 0]non-8-yl]-5,6,8-trifluoro-1,4-dihydrooil 4-oxo-3-quinolinecarboxylic acid, VMelting point: 220-222 0 C (with decomposition) (from glycol monomethyl ether) [iId -57* CHCl 3 Example 0 F COGH
C
2
H
5 0 2 C N I N I The reaction is carried out with l-cyclopropyl-6,8- Idif luoro-1, 4-dihydro-7 -(trans -2 -oxa-5, 8-diaza 3. 0]non- 8-yl)-4-oxo-3-quinolinecarboxylic acid analogously to Le A28 100 117- It Example 36 and l-cyclopropyl-7- (trans-2-ethoxycarbonyl-vinyl] -trans-2-oxa-5, 8-diaza [4.3.0 ]non-8-yl- 6 ,8-difluoro-1,4-dihydro-4-oxo 3-quinolinecarboxylic acid is obtained.
Melting point: 266-268 0 C (with decomposition) (from glycol monomethyl ether).
Example 56
COOH
CH
3 00C 0 0
F
N tran s, rac.
0 l-Cyclopropyl-6, 8-dif'luoro-l, 4-dihydro-7- (trans-2-oxa- 8-diaza[4.3.0 ]non-8-yl) -4-oxo-3-quinolinecarboxylic acid is reacted with methyl propiolate analogously to Example 36 and l-cyclopropyl-7- (trans-2-methoxycarbonyl-vinyl) -trans-2-oxa-5, 8-diaza non-8-yl] E ,8-difluoro-1 ,4-dihydro--4-oxo-3-quinolinecarboxylic acid is obtained.
Melting point: 275-277 0 C (with decomposition).
%4* Le A 28 100-18- 118

Claims (4)

1- C-CHi3 or N, X1 -rePreSents Hi, halogen, or NH 2 R' represents CI-C 3 alk3Y-, FCl 2 C- 2 UYCIOPrO-DY1 Or phenyl which is opitionally monosubstituted to trisuabstituted by haloge4, or A and R' together can denote ;a bridge of the struc~ture C-o-CII 2 CH (C21)-3 R 2 zrepresen'ts H, C1-C.3-alkyl which is optionally substitut;e!d by hyd.roxyl, haloge5n or amino or methyl1-2-oxo-l, 3-dioxol-4-y2L-methyl, B represents a radical of the formulae .a I, S a I~ 119 ZTO IE ~~ToI~j NOSITIMQ11100 RAVU 8T9 9, IT 61O6 OSOT993 9 T90o TV:TT 96. W69 fi N R'P Y \-j N R 4 N Y I NN R 4 'N Y R N Y N Y in which represents 0 or UH 2 and R 3 represents C 2 -C 5 -oxoalkylr- CH-CO-CrH CE 2 CH 2 C 2 R', R OC-CH=C-CO 2 TU, -CH-C~H-CO 2 R' or CH2Cli 2 -CN, in which R' denotes hydrogen or C 1 -C:3-alkyl, 44 1 4 t 444 4 4444 o j, I I *444 *54' 04
9. 44 4 4 4 C 44 4 a," tiLt represents HI c-C 3 -alkyll 5-methYl--2-OXO-1 3- dioxol. 4-yl-methyl, C-,-CS-OXOal)'J-. CH 2 CEC11CC$OR'4 R&02C-CH=C-CQ 2 R',p -CH=CHi-CD2R' or In which Rr denotes hydrogen or C,-Cn-alkyl and pharraacetically utilisable hydrates and acid addition salts thezeof and the alkali metal, alkaline earth metal, silver and guanidinium salts o~f the underlying carboxylic acids, excluding the compound l,cyclopropyl-6,8-difluoro-1 ,4-dihiydro-7- (2-oxa-5,8-diazabicyco4.3.OInon-8-y1 )-4-oxo-3- quirlolifecarboxylic acid-- 4 41 4 44 .4 *4 4 44 4 41 4 4 120 F LJ CTOO~ NOSITIO) SHIA.VC OROT99 9 T9S zr:TT 96, t'o/69 00 0 10 2. Quinolone- and naphthyridone-carboxylic acid derivatives of the formula according to Claim 1, in which A represents CH, CF, CCl, C-OCH, or N, Xi represents H, F, Cl, Br, NH 2 or CH., R 1 represents C 2 H 5 cyclopropyl or 2,4- difluorophenyl, or A and R 1 together can denote a bridge of the structure C-O-CH 2 -CH(CH 3 R 2represents H, CH 3 CAH or 5-rethyl-2-oxo-l,3- dioxol-4-yl-inethyl, B represents a radical of the formulae N N N N N H -1 H H H H -7P tlu R N YR 4 NW Y R N Y R N Y R4N Y in which represents 0 or CH 2 and 3 represents CH 2 -CO-CH 3 1 CH 2 -CO-C 6 ,H 5 CH 2 CH 2 -CO-CH 3 CH 2 CH 2 CO 2 RI, R' 0 2 C-CH=C-CO 2 -CH=CH-CO 2 R' or CH 2 CH 2 -CN, in which R' denotes Cl-C 2 -alkyl, 041 Le A 28 100-12 121 R 4 represents H, Cl-C 3 -alkyl, 5-methyl-2-oxo-l,3- dioxol -4 -yl -methyl, CHz-CO-CH 3 CH 2 -CO-C 6 H 5 CH 2 CH 2 -CO-CH 3 I CH 2 CH 2 CO 2 R' R'0 2 C-CH=C-CO 2 R', -CH=CH-CO 2 R' or CH 2 CH 2 -CN, in which R' denotes Cl-C 2 -alkyl, ~4 00 and pharmaceutically utilisable hydrates and acid addition salts thereof and the alkali metal, alkaline earth metal, silver and guanidinium salts of the underlying carboxylic acids. 3. Quinolone- and naphthyridone-carboxylic acid derivatives of the formula according to Claim 1, in which A represents CH, CF, CCl, C-OCH 3 or N, 0~0. X 1 represents H, F, Cl, Br, NH 2 or CH 3 1 R 1 represents C 2 H 5 cyclopropyl or 2,4- difluorophenyl, or A and R 1 together can denote a bridge of the structure C-O-CH 2 -CH(CH 3 R 2 represents H, CH 3 C 2 H. or 5-methyl-2-oxo-l,3- dioxol-4-yl-methyl, B represents a radical of the formulae Le A 28 100-12 122 L I N N N N H H Hh H-7/ RN Y R N Y RN Y RN Y \-VJ in which Y represents 0 or CHI and 4 R represents CE 2 -CO-CH,, CHI-CO-CgH 5 CiI 2 CRH-Co-CH 3 CII. 2 CH 2 COR', R'0 2 C-CH=C-CO 2 -CHI=CH-C0 2 R' or Ci 2 CH 2 -CN, in which R' denotes CI-C,-akyl, and oha-riaceutically utilisable hydrates and acid addition salts thereof and the alkali metal, 00: 10 alkaline earth inetal, silver and guanidinium salts of the underlying carboxylic acids. 4. 8-chloro-1-cycloDropyl-7-( [S,S]-2,8-diazabicyclo- i4.3.0]non-8-yl)-6-fluoco-l, 4-dihydro-4 quinolinecaoxylic acid and pharmaceutically utilisable hydrates and acid addition salts thereof 0* 4 and the alkali metal, alkaline earth metal, silver and guanidiniium salts of the underlying carboxylic :acids.. 123 VTO I NOSI1103 MAWC( 0999 TUX~ ZV:TT 96. VO/6Z N OY. 000 r~ o roci D I 11 o .r 1. rr r tir ,ri Quinolonecarboxylic acids of the group consisting of 1-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.jnon- 8-yl)-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acid, 1-cyclopropyl-7-( [S,S]-2,8-diazabicyclo[4.3.0]non- 8-yl)-6-fluoro-1,4-dihydro-4-oxo-3 quinolinecarboxylic acid, 1-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non- B-yl)-5,618-trifluoro-l,4-dihydro-4-oxo-3- quinolinecarboxylic acid and salts thereof. 6. Process for the preparation of quinolone- and naphthyridone-carboxylic acid derivatives according to Claims 1 to 3 of the formula (I) in which A represents CH, CF, CC1, C-OCH 3 C-CH3 or N, X 1 represents H, halogen, NH 2 or CH, Ri represents C-C-alkyl, FCH 2 CH 2 cyclopropyl or phenyl which is optionally monosubstituted to trisubstituted by halogen, or A and R' together j L i Le A 28 100 -124 i. can denote a bridge of the structure C-O-CH 2 CH (CHO)- R 2represents H, Cl-C 3 -alkyl which is optionally substituted by hydroxyl, halogen or amino or 5-methyl-2-oxo-l, 3-dioxol-4-yl-methyl, and B represents a radical of the formula RNP' in which 04 t RY represt 0yroe or CH 2 and kyl 0,01 0 N A N HNR *j) Le A 28 100-12 125 II in which A, Y, X 1 R 1 and R 2 have the abovementioned meaning, is reacted with a compound of the formula (III) R 3 -X 3 (III) in which R 3 has the abovementioned meaning, and 0400 I 3 0o t vIf 0 0 X 3 represents halogen, in particular chlorine, bromine or iodine, if appropriate in the presence of acid binders. 7. Process for the preparation of quinolone- and naphthyridone-carboxylic acid derivatives according to Claims 1 to 3 of the formula (I) in which A represents CH, CF, CC1, C-OCH 3 C-CH 3 or N, X 1 represents H, halogen, NH 2 or CH 3 R 1 represents Cl-C 3 -alkyl, FCH2CH 2 cyclopropyl or phenyl which is optionally monosubstituted to trisubstituted by halogen, or A and R 1 together can denote a bridge of the structure Le A 28 100 126 t 1 i 1 L C-O-CHZ-CH (CH 3 R2 represents cl-c3-alky1 wh.,c. i~s optionally substitutied by hydroxyl, halogen or amino oir 5-methyl-2-oxo-1, 3-dioxol-4-y-nei,. y1 and B represents a radica.l of the formula in which R Y represents 0 or CHI~ and nrepresents CH2CH 2 -C0-CH3, CH 2 CH 2 -C02R' R' 0 2 C-CH=C-Co2,, -CH--CH-CO 2 or CH 2 Cfl2-CN, in which R' denotes hydrogen or C 1 -C.3-alkyl, characterised in that a compound o± the formula (11) xi F 00R 2 12 I IC,' C o C C C in which 127 2TOlin 210 F~j NOSITOD M~AVU 090TZ9Z Z T9Q 9r:TT 96. to/6z Le A 28 100 114 r I. IIILL-- A, Y, X 1 R 1 and R 2 have the abovementioned meaning, is reacted with a Michael acceptor such as dialkyl acetylenedicarboxylate, alkyl propiolate or a compound of the formula (IV) CH 2 =CH-R (IV) .4 0000# o. I in which R 5 represents COCH 3 CO 2 R' or CN. 8. Process for the preparation of quinolone- and naphthyridone-carboxylic acid derivatives according to Claims 1 to 3 of the formula in which A represents CH, CF, CC1, C-OCH 3 C-CH 3 or N, X 1 represents H, halogen, NH 2 or CH 3 R 1 represents Ci-C 3 -alkyl, FCH 2 CH2-, cyclopropyl or phenyl which is optionally monosubstituted to trisubstituted by halogen, or A and R 1 together can denote a bridge of the structure C-O-CH 2 -CH(CH 3 R 2 represents h, Ci-C 3 -alkyl which is optionally substituted by hydroxyl, halogen or amino or 5-methyl-2-oxo-l,3-dioxol-4-yl-methyl, 0 0 A I rr1 1 t 1 Le A 28 100 128 IN- B represents a radical of the formulae, N N N N H- H H- H- H H' 4- H (VI) RN \Y RN Y R N Y R N Y in which Y represents 0 or CH 2 R 4 represents Hi, CI-C 3 -alkyl, C 2 -C 5 -oxoalkyl, CH 2 -CO- C 6 H 5 CH 2 CH 2 CO 2 R' R'I0 2 C-CH=C-CO 2 -CH=CH-CO 2 R'I or CH 2 CH 2 -CN or represents 5-methyl-2-oxo-l, 3-dioxol- 4-yl-methyl, in which R' denotes hydrogen or Cl-C 3 -alkyl, characterised in that compounds of the formula (V) x 0 0414 F COOR 2 (V 44X A N I in which A, R 1 R 2 and X1 have the abovementioned meaning and Le A 28 100 -129- X 2 represents halogen, in particular fluorine or chlorine, are reacted with enantiomerically pure compounds of the formulae (VI) H H H H N N N N H H H PHH.- .H (VI) R 4 N Y R 4 N Y R 4 N Y RN Y I in which Y represents 0 or CH 2 and R 4 represents H or C 1 -C 3 -alkyl, if appropriate in the presence of acid scavengers, and the reaction product is optionally further reacted with a compound of the formula (liIa) SR-X 3 (IIa) in which i X 3 has the abovementioned meaning and R 4 represents Cz-Cs-oxoalkyl, CH 2 -CO-C 6 H 5 CH 2 CH 2 CO 2 R' Le A 28 100 130- MEN or C11 2 C 2 -c'T, in whi ch R1 denotes hydrogen or Cl-C, 3 -alkyl, or with a Michael acceptor such as dialkyl acetylenedicarboxylate, alkyl propiolate or a cornapound of the formula (IV) in which Ri represents COCH:, C0 2 P2 or CN. A -,,iidicament containing a compound according to any on~e of ClAi-:is I. to 5, in aseociation with a pharmaceutically acceptab~le diluent or carrier. A method for the pro~phylaxis and chemotherapy of local. and systemic infections in hunian iund veterinary medicine I wherein there is administered, to a subject perceived to be in need of such treatment, a compound according to any one of Claims 1 to 5 or a medicamnent according to Claim 9J t 11. A method for the preservation of inorganic and organic V. materials wherein there is applied,' to such a material K perceived to be in need of such preservation, a compound according to any one of Claims 1 to S.
12. A compound according to Claim I subztantially as herein described with reference to any one of the foregoing examples thereof. 9TO In 9TO~~j NOSITIO0D SaIfaV O90TZ9Z 9 TT 9, 'O6 CV:TT 96, VO/69 ii WI I _I 132
13. A. process accoring to any one of Claims G to 8 stbstantially as herein described with reference to any one of the foregoing examples thereof. DATED this 26th day of April 1996 BAYER ATI1E=GESELLSCMAPT By Its Patent Attorneys DAVIES COLLISON CAVE tt o t *ttt1 II It C. I .4, 0P 044 3 d o if ZT02 NOSITIO3 SIMVa 090TZ9Z 9 T9,. Ctr:TT 96, PO/6Z I I Guinolone- and naL Idone-carboxvlic acid derivatives ABSTRACT OF THE DISCLOSURE The invention relates to new quinolone- and naphthyridone carboxylic acid derivatives, processes for their preparation and also antibacterial agents and feed additives coramiing them. S 04#C o OCS CC 4* o Ci CCC. La I Yr 0444 Le A 28 100
AU31054/93A 1992-01-10 1993-01-06 Quinolone- and naphthyridone-carboxylic acid derivatives Expired AU669502B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE4200414 1992-01-10
DE4200414A DE4200414A1 (en) 1992-01-10 1992-01-10 New quinoline and naphthyridinone-carboxylic acid derivs.
DE4208792 1992-03-19
DE4208789A DE4208789A1 (en) 1992-03-19 1992-03-19 New quinoline and naphthyridinone-carboxylic acid derivs.
DE4208789 1992-03-19
DE4208792A DE4208792A1 (en) 1992-03-19 1992-03-19 New quinoline and naphthyridinone-carboxylic acid derivs.

Publications (2)

Publication Number Publication Date
AU3105493A AU3105493A (en) 1993-07-15
AU669502B2 true AU669502B2 (en) 1996-06-13

Family

ID=27203290

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31054/93A Expired AU669502B2 (en) 1992-01-10 1993-01-06 Quinolone- and naphthyridone-carboxylic acid derivatives

Country Status (16)

Country Link
EP (1) EP0550903A1 (en)
JP (3) JPH05271229A (en)
KR (1) KR100251886B1 (en)
CN (3) CN1043142C (en)
AU (1) AU669502B2 (en)
CA (1) CA2086914C (en)
CZ (1) CZ289076B6 (en)
FI (3) FI104174B1 (en)
HU (1) HU219488B (en)
MX (1) MX9207604A (en)
MY (1) MY115416A (en)
NO (1) NO301420B1 (en)
NZ (1) NZ245640A (en)
PL (1) PL174853B1 (en)
SK (3) SK282971B6 (en)
TW (1) TW209865B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04445A (en) 1990-04-17 1992-01-06 Fuji Photo Film Co Ltd Processing method for silver halide color photosensitive material
EP0458131B1 (en) 1990-05-09 1997-08-06 Fuji Photo Film Co., Ltd. Photographic processing composition and processing method using the same
DE4121214A1 (en) * 1991-06-27 1993-01-14 Bayer Ag 7-AZAISOINDOLINYL CHINOLONE AND NAPHTHYRIDONE CARBONIC ACID DERIVATIVES
CA2112165C (en) * 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
KR0148277B1 (en) * 1993-01-18 1998-11-02 채영복 Novel fluoroquinolone derivatives and process for the preparation thereof
DE4301246A1 (en) * 1993-01-19 1994-07-21 Bayer Ag Quinolone and naphthyridonecarboxylic acid derivatives
JP3372994B2 (en) 1993-06-11 2003-02-04 富士写真フイルム株式会社 Processing method of silver halide color photographic light-sensitive material
DE4329600A1 (en) * 1993-09-02 1995-03-09 Bayer Ag Pyrido [1,2,3-d, e] [1,3,4] benzoxadiazine derivatives
KR950018003A (en) * 1993-12-09 1995-07-22 스미스클라인 비참 피엘씨 Novel quinolone derivatives and methods for their preparation
DE4342186A1 (en) * 1993-12-10 1995-06-14 Bayer Ag One-pot process for the production of 3-quinolonecarboxylic acid derivatives
DE4418510A1 (en) * 1994-05-27 1995-11-30 Bayer Ag 1,9-bridged thiazolol [3,4-a] quinoline derivatives
WO1996040981A1 (en) * 1995-06-07 1996-12-19 Bayer Aktiengesellschaft Testing device for determining the susceptibility of microorganisms to inhibitory agents
DE19546249A1 (en) * 1995-12-12 1997-06-19 Bayer Ag New crystal modification of 1-cyclopropyl-7 - ([S, S] -2,8-diazabicyclo [4,3,0] non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4 -oxo-3-quinoline carboxylic acid hydrochloride (CDCH), process for its preparation and pharmaceutical preparations containing it
DE19652239A1 (en) * 1996-12-16 1998-06-18 Bayer Ag Use of 7- (2-oxa-5,8-diazabicyclo [4.3.0] non-8-yl) -quinolone and naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and the associated gastroduodenal diseases
DE19735198A1 (en) * 1997-08-14 1999-02-18 Bayer Ag Optical resolution of cis- or trans-pyrrolo:piperidine derivatives
KR100531065B1 (en) * 1997-09-25 2005-11-28 바이엘 악티엔게젤샤프트 Medicament Formulation with a Controlled Release of an Active Agent
DE19751948A1 (en) * 1997-11-24 1999-05-27 Bayer Ag Rapid preparation of 8-alkoxy-quinolone-carboxylic acid derivative antibacterial agent, e.g. gatifloxacin, in high purity
DE19821039A1 (en) * 1998-05-11 1999-11-18 Bayer Ag Production of (S,S)-8-benzyl-2,8-diazabicyclo(4.3.0)nonane useful as intermediate for antibiotic moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020661A1 (en) * 1998-09-30 2002-05-22 Alcon Lab Inc A PHARMACEUTICAL COMPOSITION TOPICA OFTALMICA, OTICA OR NASAL AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
CZ292069B6 (en) * 1998-11-10 2003-07-16 Bayer Aktiengesellschaft Pharmaceutical preparation containing moxifloxacin, process of its preparation and use
CA2367373C (en) 1999-03-17 2011-09-20 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions
DE19927412A1 (en) 1999-06-16 2000-12-21 Bayer Ag Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo [4.3.0] nonane
DE19931115A1 (en) * 1999-07-06 2001-01-11 Bayer Ag Racemization of R, S-dioxo-benzylpyrrolopiperidine
DE19962470A1 (en) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Use of chemotherapy drugs
DE10226923A1 (en) 2002-06-17 2003-12-24 Bayer Ag Process for the enantiomer enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo [4.3.0] nonane
ES2319125T3 (en) * 2003-11-20 2009-05-04 Chemi S.P.A. POLYMORPHES OF ACID CHLORHYDRATE 1-CICLOPROPIL-7 - ((S, S) -2,8-DIAZADICICLO (4.3.0) -NON-8-IL) -6-FLUORO-1,4-DIHYDRO-8-METOXI- 4-OXO-3-CARBOXYLIN CHINOLINE AND METHODS FOR THE PREPARATION OF THE SAME.
ITMI20032259A1 (en) * 2003-11-20 2005-05-21 Chemi Spa NEW POLYMORPHOUS OF ACID 1-CYCLOPROPYL-7- (S, S-2,8-DIAZABICLO-4.3.0-NON-8-IL) -6-FLUORO-1,4-DIIDRO-8-METOSSI-4-OXO -CHINOLIN CARBOSXYL CHLORIDRATE AND METHODS FOR ITS PREPARATION
US7759362B2 (en) 2004-04-21 2010-07-20 Institut Of Medicinal Biotechnology Chinese Academy Of Medical Sciences Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof
CN1244582C (en) * 2004-04-21 2006-03-08 中国医学科学院医药生物技术研究所 Compound of quinolone carboxylic acid, preparation method and medicinal usage
ES2284380B1 (en) * 2006-03-10 2008-11-01 Quimica Sintetica S.A. PROCEDURE FOR THE PREPARATION OF MOXIFLOXACINO AND MOXIFLOXACINO CHLORHYDRATE.
EP2436381A1 (en) 2006-06-27 2012-04-04 Sandoz AG Crystallization of hydrohalides of pharmaceutical compounds
IN2014MN02582A (en) 2006-11-13 2015-09-11 Cipla Ltd
WO2008059521A2 (en) * 2006-11-14 2008-05-22 Msn Laboratories Limited Novel process for the preparation of moxifloxacin hydrochloride and a novel polymorph of moxifloxacin
US7692015B2 (en) 2007-01-05 2010-04-06 Zheqing Wang Economical process for preparing (S, S)-2, 8-diazabicyclo[4.3.0]nonane and its enantiomer
WO2008102188A1 (en) 2007-02-22 2008-08-28 Tibor Nagy Procedure to manufacture and use beer and other types liquids treated with neodimium magnet
EP2083010A1 (en) 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
IT1393337B1 (en) * 2009-03-06 2012-04-20 Italiana Sint Spa SUMMARY OF (4AS, 7AS) -OTTAIDRO-1H-PIRROLO [3,4-B] PYRIDINE
EP2423211B1 (en) * 2009-04-20 2014-04-16 Kaneka Corporation Processes for producing (1s,6s)- or (1r,6r)-cis-2,8-diazabicyclo[4.3.0]nonane and intermediate thereof
IT1398952B1 (en) * 2010-03-19 2013-03-28 F S I Fabbrica Italiana Sint PROCESS OF PREPARATION OF MOXIFLOXACINE AND ITS SALTS
CN101941969B (en) * 2010-09-30 2012-05-23 江苏正大丰海制药有限公司 Preparation method of moxifloxacin hydrochloride
CN102675308A (en) * 2011-03-17 2012-09-19 苏州中科天马肽工程中心有限公司 Method for preparing 8-benzyl-2,8-diazabicyclo(4.3.0) nonane
CN102675307A (en) * 2011-03-17 2012-09-19 苏州中科天马肽工程中心有限公司 Method for preparing chiral compound 8-phenethyl-2,8-diazabicyclo[4.3.0]nonane
ITTO20110705A1 (en) 2011-07-29 2013-01-30 Italiana Sint Spa PROCEDURE FOR THE PREPARATION OF MOXIFLOXACINE CHLORIDRATE AND RELATED INTERMEDIATES
CN102964346B (en) * 2011-09-01 2015-04-22 中国中化股份有限公司 Preparation method of (S, S)-octahydro-6H-pyrrolo[3, 4-b]pyridine
CN103044418B (en) * 2011-10-14 2015-02-04 上海朴颐化学科技有限公司 Asymmetric synthesis method, relevant raw materials and preparation method of (S,S)-2,8-diazabicyclo[4,3,0] nonane
CN102408427B (en) * 2011-10-22 2012-12-12 浙江普洛康裕制药有限公司 Preparation method for moxifloxacin intermediate (1S, 6R)-8-benzyl-7, 9-dioxy-2, 8-diazabicyclo [4.3.0] nonane
BRPI1106900A2 (en) 2011-12-26 2013-11-05 Ems Sa SOLID PHARMACEUTICAL COMPOSITION UNDERSTANDING ANTIBOTH FAMILY OF QUINOLONES AND THE PROCESS OF OBTAINING THEM
FR2992218B1 (en) 2012-06-22 2015-01-23 Rivopharm Sa PHARMACEUTICAL COMPOSITION OF MOXIFLOXACIN HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME
EP2928892B1 (en) 2012-12-04 2018-03-21 Mankind Pharma Ltd. An improved process for the preparation of moxifloxacin hydrochloride
CN103012452B (en) * 2012-12-25 2015-12-02 浙江新和成股份有限公司 The preparation method of a kind of Moxifloxacin and hydrochloride thereof
UA106556C2 (en) * 2013-05-13 2014-09-10 Наталья Николаевна Деркач Method of obtaining (1-cyclopropyl -6- fluoro-1,4-dihydro methoxy -8 -7 - [(4as, 7as) - oktahydro -6n- pyrrolo [3,4-pyridine bsch - 6- yl] -4-oxo-3-hinolinkarbonovoyi acid
CN103724262B (en) * 2013-12-10 2016-05-18 广东省第二人民医院 A kind of fluoquinolone silver compound and its production and use
CN104860944A (en) * 2015-06-09 2015-08-26 内蒙古东北六药集团有限公司 Production method of moxifloxacin hydrochloride
CN108872413B (en) * 2018-04-27 2021-06-08 山东齐都药业有限公司 Method for detecting enantiomer content in (S, S) -2, 8-diazabicyclo [4,3,0] nonane
CN110627768B (en) * 2018-06-22 2021-11-09 扬子江药业集团有限公司 Preparation method of moxifloxacin degradation impurity J
CN110183445B (en) * 2019-06-28 2021-08-24 昆明学院 Synthetic method of moxifloxacin and derivatives thereof
RU2713932C1 (en) * 2019-10-31 2020-02-11 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Fluoroquinolone compounds based on pyridoxine derivatives, having antibacterial properties
CN112939849B (en) * 2019-12-11 2022-05-03 浙江新和成股份有限公司 (S, S) -2, 8-diazabicyclo [4.3.0] nonane intermediate and preparation method and application thereof
CN110981874A (en) * 2020-03-05 2020-04-10 北京四环生物制药有限公司 Preparation method of moxifloxacin hydrochloride
CN112409352B (en) * 2020-11-20 2022-05-24 华南理工大学 Moxifloxacin drug derivatives and preparation method and application thereof
CN112574197B (en) * 2020-12-07 2021-12-31 泰安汉威集团有限公司 Chiral purification method of compound C

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5123690A (en) * 1989-03-13 1990-09-13 Bristol-Myers Squibb Company 5-substituted-1,4-dihydro-4-oxo-nephthyridine-3-carboxylate antibacterial agents
AU1028392A (en) * 1988-07-15 1992-02-27 Bayer Schering Pharma Aktiengesellschaft Intermediates for preparing 7-(1-pyrrolidinyl) -3-quinolone- and -naphthyridone- carboxylic acid derivatives
AU638005B2 (en) * 1989-04-03 1993-06-17 Bayer Aktiengesellschaft 5-alkylquinolonecarboxylic acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0754229B2 (en) * 1987-09-28 1995-06-07 松下冷機株式会社 refrigerator
JPH03188080A (en) * 1989-12-15 1991-08-16 Banyu Pharmaceut Co Ltd Pyridonecarboxylic acid derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1028392A (en) * 1988-07-15 1992-02-27 Bayer Schering Pharma Aktiengesellschaft Intermediates for preparing 7-(1-pyrrolidinyl) -3-quinolone- and -naphthyridone- carboxylic acid derivatives
AU5123690A (en) * 1989-03-13 1990-09-13 Bristol-Myers Squibb Company 5-substituted-1,4-dihydro-4-oxo-nephthyridine-3-carboxylate antibacterial agents
AU638005B2 (en) * 1989-04-03 1993-06-17 Bayer Aktiengesellschaft 5-alkylquinolonecarboxylic acids

Also Published As

Publication number Publication date
CN1061351C (en) 2001-01-31
CA2086914A1 (en) 1993-07-11
JPH05271229A (en) 1993-10-19
FI104174B (en) 1999-11-30
FI990207A (en) 1999-02-03
MY115416A (en) 2003-06-30
EP0550903A1 (en) 1993-07-14
NO924978L (en) 1993-07-12
SK396692A3 (en) 2002-09-10
HUT64065A (en) 1993-11-29
CN1043142C (en) 1999-04-28
FI930049A0 (en) 1993-01-07
HU9300034D0 (en) 1993-04-28
JP2003026574A (en) 2003-01-29
NO924978D0 (en) 1992-12-22
SK285223B6 (en) 2006-09-07
SK2232000A3 (en) 2006-05-04
SK282971B6 (en) 2003-01-09
FI104174B1 (en) 1999-11-30
CN1074218A (en) 1993-07-14
FI930049A (en) 1993-07-11
FI110943B (en) 2003-04-30
CN1212256A (en) 1999-03-31
AU3105493A (en) 1993-07-15
FI113771B (en) 2004-06-15
PL297338A1 (en) 1993-09-06
NO301420B1 (en) 1997-10-27
SK2212000A3 (en) 2006-05-04
CZ396692A3 (en) 1993-08-11
FI20020059A (en) 2002-01-11
CN1075499C (en) 2001-11-28
JP4111431B2 (en) 2008-07-02
FI990207A0 (en) 1999-02-03
PL174853B1 (en) 1998-09-30
CZ289076B6 (en) 2001-10-17
CN1192440A (en) 1998-09-09
SK285155B6 (en) 2006-07-07
KR100251886B1 (en) 2000-07-01
CA2086914C (en) 2005-03-15
KR930016421A (en) 1993-08-26
TW209865B (en) 1993-07-21
NZ245640A (en) 1995-03-28
MX9207604A (en) 1993-10-01
HU219488B (en) 2001-04-28
JP2003048890A (en) 2003-02-21

Similar Documents

Publication Publication Date Title
AU669502B2 (en) Quinolone- and naphthyridone-carboxylic acid derivatives
AU650316B2 (en) Intermediates for preparing 7-(1-pyrrolidinyl) -3-quinolone- and -naphthyridone- carboxylic acid derivatives
DE4234078A1 (en) Quinolonecarboxylic acids
DE4230804A1 (en) 7-isoindolinyl quinolone and naphthyridone derivatives
DE4234330A1 (en) Quinolonecarboxylic acids
EP0705828B1 (en) Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents
CA2443307C (en) Quinolone- and naphthyridone-carboxylic acid derivatives
RU2105770C1 (en) Quinolone-and naphthiridonecarboxylic acid derivatives in admixture with isomers or individual isomers, hydrates and salts thereof, and pharmaceutical composition
KR100270898B1 (en) Quinolone- and Naphthyridone-Carboxylic Acid Derivatives
AU668286B2 (en) Diazabicyclo(4.3.0)nonane and (3.3.0)octane heterocycles
EP0704443B1 (en) Quinolone and naphthyridone carboxylic acid derivatives
IE19970856A1 (en) 7-(1-Pyrrolidinyl)-3-quinolone and naphthyridone carboxylic acid derivatives, method for their preparation and for substituted mono- and bicyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions
IE84193B1 (en) 7-(1-Pyrrolidinyl)-3-quinolone and naphthyridone carboxylic acid derivatives, method for their preparation and for substituted mono- and bicyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: BAYER HEALTHCARE AG

Free format text: FORMER OWNER WAS: BAYER AKTIENGESELLSCHAFT